US 9,307,928 B1Grant
Plethysmographic respiration processor
Issue Date:2016-04-12
•18 Claims
•18 Drawing Sheets
Abstract
A plethysmographic respiration processor is responsive to respiratory effects appearing on a blood volume waveform and the corresponding detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of respiration rate. A preprocessor identifies a windowed pleth corresponding to a physiologically acceptable series of plethysmograph waveform pulses. Multiple processors derive different parameters responsive to particular respiratory effects on the windowed pleth. Decision logic determines a respiration rate based upon at least a portion of these parameters.
Metadata
Assignee
- MASIMO CORPORATION
Inventors
- Ammar Al-Ali
- Anmol Majmudar
Application Information
Application Number:US 13/076,423
Filing Date:2011-03-30
Priority Date:2010-03-30
Art Unit:3735
Classifications
IPC:
A61B5/08
Patent Drawings (18 sheets)
Description
Priority Claim to Related Provisional Applications
[0001] The present application claims priority benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 61/319,256, filed Mar. 30, 2010, titled Plethysmographic Respiration Processor and U.S. Provisional Patent Application Ser. 61/364,141, filed Jul. 14, 2010, titled Plethysmographic Respiration Detector; all of the above-cited provisional patent applications are hereby incorporated by reference herein.
Background of the Invention
[0002] Pulse oximetry is a widely accepted noninvasive procedure for measuring the oxygen saturation level of arterial blood, an indicator of a person's oxygen supply. A typical pulse oximetry system utilizes an optical sensor clipped onto a fingertip to measure the relative volume of oxygenated hemoglobin in pulsatile arterial blood flowing within the fingertip. Oxygen saturation (SpO2), pulse rate and a plethysmograph waveform, which is a visualization of pulsatile blood flow over time, are displayed on a monitor accordingly.
[0003] Conventional pulse oximetry assumes that arterial blood is the only pulsatile blood flow in the measurement site. During patient motion, venous blood also moves, which causes errors in conventional pulse oximetry. Advanced pulse oximetry processes the venous blood signal so as to report true arterial oxygen saturation and pulse rate under conditions of patient movement. Advanced pulse oximetry also functions under conditions of low perfusion (small signal amplitude), intense ambient light (artificial or sunlight) and electrosurgical instrument interference, which are scenarios where conventional pulse oximetry tends to fail.
[0004] Advanced pulse oximetry is described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, which are assigned to Masimo Corporation (“Masimo”) of Irvine, Calif. and are incorporated by reference herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,813,511; 6,792,300; 6,256,523; 6,088,607; 5,782,757 and 5,638,818, which are also assigned to Masimo and are also incorporated by reference herein. Advanced pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SpO2, pulse rate (PR) and perfusion index (PI) are available from Masimo. Optical sensors include any of Masimo LNOP®, LNCS®, SofTouch™ and Blue™ adhesive or reusable sensors. Pulse oximetry monitors include any of Masimo Rad-8®, Rad-5®, Rad®-5v or SatShare® monitors.
[0005] Advanced blood parameter measurement systems are described in at least U.S. Pat. No. 7,647,083, filed Mar. 1, 2006, titled Multiple Wavelength Sensor Equalization; U.S. patent application Ser. No. 11/367,036, filed Mar. 1, 2006, titled Configurable Physiological Measurement System; U.S. patent application Ser. No. 11/367,034, filed Mar. 1, 2006, titled Physiological Parameter Confidence Measure and U.S. patent application Ser. No. 11/366,208, filed Mar. 1, 2006, titled Noninvasive Multi-Parameter Patient Monitor, all assigned to Masimo Laboratories, Irvine, Calif. (Masimo Labs) and all incorporated by reference herein. Advanced blood parameter measurement systems include Masimo Rainbow® SET, which provides measurements in addition to SpO2, such as total hemoglobin (SpHb™), oxygen content (SpOC™), methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSposable™ and reusable sensors. Advanced blood parameter monitors include Masimo Radical-7™, Rad-87™ and Rad-57™ monitors, all available from Masimo. Such advanced pulse oximeters, low noise sensors and advanced blood parameter systems have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.
Summary of the Invention
[0006] Advantageously, a plethysmographic respiration processor provides respiration rate readings based upon optical properties of pulsatile blood flow. The respiration rate so derived may be used alone or combined with respiration rate derived by various other means including, but not limited to, microphones or other acoustic sensors located to respond to various body sounds; humidity sensors located to respond to inhalation/exhalation moisture; thermistors and photodiodes located to respond to inhalation/exhalation air temperature; capacitance sensors located to respond to inhalation/exhalation air pressure; and venturi effect sensors located to respond to inhalation/exhalation air flow. In a particularly advantageous embodiment, a plethysmographic respiration detector is used in conjunction with an acoustic monitor or combined blood parameter and acoustic monitor, such as a Masimo Rainbow® SET platform and an acoustic respiration rate (RRa™) sensor available from Masimo, so as to improve the accuracy of, robustness of, or otherwise supplement acoustic-derived respiration rate measurements or other acoustic-derived respiration parameters.
[0007] One aspect of a plethysmographic respiration processor is responsive to respiration affecting blood volume and a corresponding detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of respiration rate. The plethysmographic respiration detector comprises a preprocessor, processors and decision logic. The preprocessor identifies a windowed pleth corresponding to a physiologically acceptable series of plethysmograph waveform pulses. The processors derive various spectrums of the windowed pleth. Each of the processors is configured so that its corresponding spectrum is particularly responsive to a specific respiratory effect on the windowed pleth. The decision logic determines a respiration rate based upon matching features of at least two of the spectrums.
[0008] In various embodiments, the processors comprise a baseline processor that inputs the windowed pleth and outputs a “baseline” spectrum. The baseline processor has a first signal conditioner and a first frequency transform. The first signal conditioner generates a first conditioned pleth from the windowed pleth. The first frequency transform inputs the first conditioned pleth and generates the baseline spectrum.
[0009] The processors further comprise an amplitude modulation (AM) processor that inputs the windowed pleth and outputs an “AM” spectrum. The AM processor has a second signal conditioner that generates a second conditioned pleth from the windowed pleth. A demodulator AM demodulates the second conditioned pleth to generate a demodulated pleth. A second frequency transform inputs the demodulated pleth and generates the AM spectrum.
[0010] The processors further comprise a shape modulation (SM) processor that inputs the windowed pleth and outputs a “SM” spectrum. The SM processor has a third signal conditioner that generates a third conditioned pleth from the windowed pleth. A feature extractor generates a modulated metric from the third conditioned pleth. A third frequency transform generates the SM spectrum from the modulated metric.
[0011] The decision logic has a peak detector, a comparator and a respiration rate output. The peak detector operates on at least two of the baseline spectrum, the AM spectrum and the SM spectrum so as to determine local maximums. The comparator determines if there are any local maximums from the at least two of the spectrums that occur at matching frequencies within a predetermined tolerance. A respiration rate output is generated if the comparator finds at least a two-way match. A smoother operates on multiple respiration rate outputs derived over a sliding series of the windowed pleths so as to derive a smoothed respiration rate output. A tested condition rejects the respiration rate output if it differs from the smoothed respiration rate output by more than a predetermined amount.
[0012] Another aspect of a respiration rate processor is inputting a plethysmograph waveform, determining a baseline spectrum responsive to a respiratory-induced baseline shift of the plethysmograph waveform, determining an amplitude modulation (AM) spectrum responsive to a respiratory-induced amplitude modulation of the plethysmograph waveform, determining a shape modulation (SM) spectrum responsive to a respiratory-induced shape modulation of the plethysmograph waveform, and matching at least two of the baseline, AM and SM spectrums so as to derive a respiration rate. In an embodiment, determining a baseline spectrum comprises frequency transforming the plethysmograph waveform. In an embodiment, determining an AM spectrum comprises demodulating the plethysmograph waveform so as to generate a demodulated pleth; and frequency transforming the demodulated pleth. In an embodiment, determining a SM spectrum comprises feature extracting the plethysmograph waveform so as to generate a modulated metric and frequency transforming the modulated metric.
[0013] In various other embodiments, matching comprises detecting peaks in at least two of the spectrums, comparing the detected peaks so as to find one peak from each of the at least two spectrums occurring at a particular frequency and outputting the particular frequency as the respiration rate. Windowed pleths are defined by a sliding window of acceptable portions of the plethysmograph waveform. The respiration rate output is smoothed based upon a median respiration rate calculated over multiple ones of the windowed pleths. The particular frequency is rejected if it is not within a predetermined difference of the smoothed respiration rate.
[0014] A further aspect of a respiration rate processor is a baseline processor, an AM processor, a SM processor and decision logic. The baseline processor identifies a respiration-induced baseline shift in a plethysmograph waveform. The AM processor identifies a respiration-induced amplitude modulation of the plethysmograph waveform. The SM processor identifies a respiration-induced shape modulation of the plethysmograph waveform. The decision logic compares the respiration-induced baseline shift, amplitude modulation and shape modulation so as to derive a respiration rate.
[0015] In various embodiments, the baseline processor generates a baseline spectrum from a first frequency transform of the plethysmograph waveform. The AM processor generates an AM spectrum from a second frequency transform of demodulated plethysmograph waveform. The SM processor generates an SM spectrum from a third frequency transform of a modulated metric extracted from the plethysmograph waveform. Decision logic has a peak detector and a comparator. The peak detector determines local maximums in each of the baseline spectrum, AM spectrum and SM spectrum. In an embodiment, the comparator determines a three-way match in the frequency of the local maximums in the spectrums. In an embodiment, the comparator determines a two-way match in the frequency of the local maximums in the spectrums, and a condition for accepting the two-way match compares a respiration rate determined by the two-way match to a smoothed respiration rate.
[0016] A further aspect of a plethysmographic respiration processor is responsive to respiratory modulation of a blood volume waveform or corresponding detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of a respiration parameter. A demodulator processes a sensor signal so as to generate a plethysmograph waveform. A pulse processor identifies candidate pulses from the plethysmograph waveform. A pulse modeler identifies physiologically acceptable ones of the candidate pulses. The plethysmographic respiration processor has a feature extractor, a normalizer and a feature analyzer. The feature extractor processes the acceptable pulses so as to calculate pulse features. The normalizer compares the pulse features so as to calculate a pulse parameter. The feature analyzer calculates a respiration parameter from the pulse parameter.
[0017] In various embodiments, the pulse features comprise a difference (E) between an acceptable pulse and a triangular pulse estimate; the pulse features comprise an area (A) under a triangular pulse; or the pulse features are calculated with respect to a diastolic (d) portion of an acceptable pulse and a corresponding diastolic portion of a triangular pulse. In various embodiments, the normalizer compares a diastolic difference (Ed) with a diastolic area (Ad) or the normalizer calculates Ed/Ad. In an embodiment, the feature analyzer determines the frequency spectrum of Ed/Ad so as to determine a respiration rate.
[0018] Yet another aspect of a plethysmographic respiration processor detects a tissue site response to optical radiation having a plurality of wavelengths, demodulates the response according to wavelength so as to generate a corresponding plurality of plethysmograph waveforms, identifies acceptable pulses from at least one of the waveforms and calculates a respiration parameter from the acceptable pulses. To calculate a respiration parameter, in various embodiments the processor estimates an acceptable pulse with a triangular pulse and determines a systolic portion and a diastolic portion of the acceptable pulse and the triangular pulse; compares the triangular to the acceptable pulse so as to define pulse features; normalizes the pulse features according to the systolic and diastolic portions so as to generate a pulse parameter; or analyzes the pulse parameter to derive a respiration parameter. The comparing may comprise differencing the acceptable pulse and the triangular pulse over the diastolic portion. The analyzing may comprise transforming the pulse parameter to a frequency parameter and outputting a respiration rate according to a maximum of the frequency parameter.
[0019] Additional aspects of plethysmographic respiration processor has a pulse input having physiologically acceptable pleth pulses derived from a plethysmograph waveform. A feature extractor extracts pulse features from the pulse input. The pulse features are modulated by respiration. A normalizer calculates a pulse parameter from the relative magnitude of a first one of the pulse features compared with a second one of the pulse features. A feature analyzer calculates a respiration parameter from the pulse parameter.
[0020] In various embodiments, the feature extractor may calculate a difference between a triangular pulse estimate and a corresponding pleth pulse. The feature may also calculate an area under a portion of the triangular pulses. The processor may differentiate between a systolic pulse feature and a diastolic pulse feature. The feature extractor may calculate an apex angle of the slope portion of a triangular pulse estimate. The feature analyzer may perform a frequency transform to extract a respiration rate from the pulse parameter.
Brief Description of the Drawings
[0021] FIG. 1 is a block diagram of a plethysmographic respiration processor embodiment;
[0022] FIGS. 2A-B are a block diagram of a pre-processor embodiment and a time illustration of a sliding window, respectively;
[0023] FIGS. 3A-C are a block diagram of a baseline processor, an intensity versus time graph of a baseline modulated pleth, and a baseline frequency spectrum, respectively;
[0024] FIGS. 4A-D are a block diagram of an AM processor, an intensity versus time graph of an AM pleth, and AM pleth frequency spectrum and a demodulated pleth frequency spectrum, respectively;
[0025] FIGS. 5A-D are a block diagram of an SM processor, an intensity versus time graph of an SM pleth, and graph of a shape metric versus time; and a shape metric frequency spectrum, respectively;
[0026] FIGS. 6A-B are intensity versus time graphs of a shape modulated pulse illustrating area-based shape metrics;
[0027] FIGS. 7A-B are intensity versus time graphs of a shape modulated pulse illustrating arc-length shape metrics;
[0028] FIG. 8A-D are a block diagram of an FM processor, an intensity versus time graph of an FM pleth, and graph of a dicrotic-notch based FM metric versus time; and a FM metric frequency spectrum, respectively;
[0029] FIG. 9 is a block diagram of a pre-processor embodiment;
[0030] FIG. 10 is a block diagram of a plethysmographic respiration processor embodiment;
[0031] FIGS. 11A-D are a spectrums of a combined baseline shifted and AM modulated pleth; a spectrum of a demodulated baseline shifted and AM modulated pleth; a SM spectrum; and a non-idealized spectrum, respectively;
[0032] FIG. 12 is a decision logic flowchart for advantageously deriving a robust value for respiration rate based upon a baseline, an AM and a SM processor operating on an acceptable window of pleths; and
[0033] FIG. 13 is a decision logic flowchart for advantageously deriving a robust value for respiration rate based upon a baseline, an AM and a high pass filtered (HPF) SM processor operating on an acceptable window of pleths.
[0034] FIG. 14 is a perspective view of a non-invasive physiological parameter measurement system having a monitor and a corresponding optical sensor and incorporating a plethysmographic respiration processor;
[0035] FIGS. 15A-B are graphs of light absorption profiles for pulsatile blood perfused tissue and surrounding tissue and an optical sensor detected light intensity, respectively;
[0036] FIG. 16 is block diagram of a non-invasive physiological parameter measurement system having a monitor and a corresponding optical sensor and incorporating a plethysmographic respiration processor; and
[0037] FIG. 17 is a block diagram of a modulated plethysmograph demodulator.
Detailed Description of the Preferred Embodiments
[0038] FIG. 1 illustrates a plethysmographic respiration processor 100 embodiment having a plethysmograph waveform (pleth) input 101 and a respiration rate (RR) output 104. The pleth respiration processor 100 includes a preprocessor 200, one or more pleth processors 120 and a post processor 130. The pleth 101 is derived from an optical sensor attached to a tissue site, which is in communications with a pulse oximeter or blood parameter monitor, as described with respect to FIGS. 14-17 , below. The pre-processor 200 derives acceptable pleths 112, as described in detail with respect to FIGS. 2A-B , below. The pleth processor(s) 120 each operate on acceptable pleths 112 so as to generate respiration-rated parameters 102 responsive to a person's respiration. The pleth processors 120 may operate in the time domain, the frequency domain or a mix of time or frequency domains. Pleth processors 120 are described in detail with respect to FIGS. 3-8 , below. The post-processor 130 resolves or otherwise verifies the respiration-related parameters 102 so as to derive a respiration rate and, perhaps, averages, smoothes or otherwise filters that respiration rate so as to generate the respiration rate (RR) 104 output. Advantageously, this optical sensor derived RR may be used to derive a less intrusive measure of respiration rate or used in combination with acoustic, mechanical, electrical, temperature or other sensors and monitors so as to determine a more accurate or robust measure of respiration rate. Although described herein as deriving a respiration rate, a plethysmographic respiration processor 100 output may be similarly expressed as a respiration or a breathing frequency or interval, among others.
[0039] FIGS. 2A-B illustrate a pre-processor 200 having a pleth 101 input and generating a conditioned pleth 112, as described below. The pre-processor 200 has a candidate pulse processor 220, a pulse modeler 230, a sliding window 240, a pleth windower 250 and a signal conditioner 260. A single pleth channel is selected from a multiple demodulated pleths 1705 (FIG. 17 ) as a representative pleth 101 input. In an embodiment, the representative pleth channel corresponds to the IR wavelength channel of a (two wavelength) pulse oximeter.
[0040] As shown in FIG. 2A , the pleth 101 is fed into a candidate pulse processor 220 that removes noise and artifacts and identifies the start and end of pulses that conform to various tests of physiological acceptability. In an embodiment, the candidate pulse processor 220 has curvature, low-pass filter and edge finder components that remove waveform features that do not correspond to the steep inflow phase during ventricular systole or the longer outflow phase during diastole, including the characteristic dichrotic notch and miscellaneous waveform curvature changes. Accordingly, the candidate pulse processor 220 identifies “edges” within an input waveform segment that connect a peak and subsequent valley of a pleth pulse. The candidate pulse processor 220 also has delta T, zero crossing, amplitude threshold and slope checks so as to eliminate certain of the edges that were identified by the curvature, filter and edge finder components that do not meet certain conditions. The delta T discards all the edges that are either too slow or too quick to be physiological. The zero crossing check eliminates all edges that do not cross the zero line, such as small bumps that are not peaks or valleys. The amplitude threshold check removes larger “bumps” than the zero crossing check, such as dicrotic notches. The slope check is based on the observation that in a physiological pulse, the ventricular contraction, i.e. descending pulse portion, is steeper than any subsequent trend in the ascending pulse portion. The pulse finder transforms the edges remaining after the various edge checks into candidate pulses 222, which are fed into the pulse modeler 230.
[0041] Also shown in FIG. 2A , the pulse modeler 230 takes the candidate pulses 222 and identifies which of these are acceptable pulses 232, which satisfy an internal model for a physiological plethysmographic waveform. Although the candidate pulse processor 220 performs a series of checks on edges, the pulse modeler 230 performs a series of checks on pulse features. The first component of the pulse modeler calculates relevant pulse features. The remainder of the pulse modeler checks these pulse features to identify physiologically acceptable features. The pulse features component extracts three items of information about the input candidate pulses that are needed for downstream processing by the other components of the pulse modeler including pulse starting point, period and signal strength. The downstream components include a max BPM check, a stick model check, an angle check, a ratio check and a signal strength check. The maximum beats-per-minute (max BPM) check discards pulses having a period that is below a minimum number of samples. The stick model check discards pulses where the corresponding waveform does not fit a stick model. The angle check is based on computing the angle of a normalized slope for the ascending portion of a pulse so as to discard pulses that are extremely asymmetric. The ratio check removes pulses in which the ratio between the duration of the ascending pulse portion and the duration of the descending pulse portion is less than a certain threshold. The signal strength check assigns a confidence value to each pulse, based on its signal strength, and low confidence pulses are discarded. A pulse processor 220 and a pulse modeler 230 are described in U.S. Pat. No. 6,463,311 titled Plethysmograph Pulse Recognition Processor, issued Oct. 8, 2002, assigned to Masimo Corporation and incorporated by reference herein.
[0042] Further shown in FIGS. 2A-B , the sliding window 240 defines a series of fixed-time-length (T) samples (“windows”) of pleth, where each window 242 is shifted from the previous window by a fixed time interval (Δt) 244. In an embodiment, each window is T=2125 samples (34 sec) in length at 16 msec per sample (62.5 Hz sample rate), where successive windows are shifted by Δt=2 sec. Each window is either accepted 242 or rejected 248 as designated by an acceptable window 242 output. The pleth windower 250 utilizes the acceptable windows 242 designation to accept a corresponding section of the “raw” pleth 101 input and generate a windowed (raw) pleth 252 output. That is, the pre-processor 200 advantageously allows downstream processing to operate directly on the demodulated pleth while discarding those raw pleth sections that are deemed unacceptable, based upon various pleth models and checks as described above. In an embodiment, the signal conditioner 260 demeans/detrends and bandpass filters the windowed pleth 252 to generate a conditioned pleth 112 output. In an embodiment, the bandpass filter is an IIR filter having a 12-240 bpm (beats per minute) passband. In another embodiment described below with respect to FIG. 9 , below, a pre-processor 200 generates windowed features from acceptable pulses derived from the pleth 101 input.
[0043] FIGS. 3A-B illustrate a baseline processor 300 that derives a “baseline” spectrum Fb 302 responsive to a respiration-induced baseline shift in a pleth. As shown in FIG. 3A , the baseline processor 300 has a conditioned pleth 301 input and generates a corresponding baseline spectrum Fb 302. As shown in FIG. 3B , the conditioned pleth 301 has a pleth period 381 inversely related to pulse rate (PR). Under certain conditions, an individual's respiration induces a cyclical shift in the pleth baseline 382. The cyclical shift period 383 is inversely related to respiration rate (RR). As shown in FIG. 3C , a frequency spectrum 302 of the baseline-shifted pleth 301 includes a relatively large pulse rate (PR) peak 392 and a relatively small respiration rate (RR) peak 391.
[0044] In other embodiments, a baseline processor 300 employs a time domain calculation of the conditioned pleth 301 that determines the period 383 of a cyclical baseline shift and hence respiration rate. Such a time domain calculation may be based upon envelope detection of the conditioned pleths 301, such as a curve-fit to the peaks (or valleys) of the pleth pulses. Measurements of a cyclical variation in a plethysmograph baseline are described in U.S. patent application Ser. No. 11/221,411 titled Noninvasive Hypovolemia Monitor, filed Sep. 6, 2005 and published as US 2006/0058691 A1, assigned to Masimo and incorporated by reference herein.
[0045] FIGS. 4A-B illustrate an AM processor 400 that derives an “AM” spectrum Fam 402 responsive to a respiration-induced amplitude modulation of the pleth. As shown in FIG. 4A , the AM processor 400 has a conditioned pleth 401 input and generates a corresponding AM spectrum Fam 402 that is responsive to a demodulated pleth 422. In an embodiment, the demodulator 420 squares, low pass filters (LPF) and square-roots the conditioned pleth 401 to generate a demodulated pleth 422. In an embodiment, the frequency transformation 430 utilizes a Hamming window, a chirp-Z FFT algorithm and a magnitude calculation so as to generate an AM spectrum 402 for the demodulated pleth 422.
[0046] As shown in FIG. 4B , a pleth 401 has a pleth period 471 inversely related to pulse rate (PR). Under certain conditions, an individual's respiration amplitude modulates (AM) 472 the plethysmograph 401. In particular, the modulation period 473 is inversely related to respiration rate (RR). As shown in FIG. 4C , a spectrum 480 of the pleth 401 includes a pulse rate (PR) peak 481 and respiration sidebands 482, 483 displaced by RR on either side of the PR peak 481. As shown in FIG. 4D a spectrum 402 of the demodulated pleth 422 includes a DC peak 491 resulting from the demodulated pulse rate “carrier” translated to DC and a respiration rate (RR) peak 492 resulting from the demodulated sidebands 482, 483.
[0047] An AM processor 400 is described above as demodulating 420 a conditioned pleth 401. In other embodiments, a time domain calculation of the conditioned pleth 401 determines the respiration modulation period 473 and hence the respiration rate. That time domain calculation may be based upon envelope detection of the conditioned pleth 401, such as a curve-fit to the peaks (or valleys) of the plethysmograph or, alternatively, the peak-to-peak variation. Measurements of variation in a plethysmograph envelope are described in U.S. patent application Ser. No. 11/952,940 titled Plethysmograph Variability Processor, filed Dec. 7, 2007 and published as US 2008/0188760 A1, assigned to Masimo and incorporated by reference herein.
[0048] FIGS. 5A-D illustrate a shape modulation (SM) processor 500 that derives an “SM” spectrum Fs 502 responsive to a respiration-induced shape modulation of the pleth. As shown in FIG. 5A , the SM processor 500 has a conditioned pleth 501 input and generates a corresponding SM spectrum Fs 502. In an embodiment, the SM processor 500 includes a feature extractor 520, a high pass filter (HPF) 530 and a frequency transform 540. In another embodiment, the SM processor includes the feature extractor 520 and a frequency transform 540, but excludes the high pass filter 530. The feature extractor 520 generates a shape-based modulated metric 522, such as E/A described below. In an embodiment, the HPF 530 is a time-domain difference filter that calculates yn+1−yn so as to remove an erroneous first (low frequency) peak in the SM spectrum Fs 502. In an embodiment, the frequency transformation 540 utilizes a Hamming window, a chirp-Z FFT algorithm and a magnitude calculation so as to generate the SM spectrum 502 for each windowed conditioned pleth 501.
[0049] As shown in FIG. 5B , a pleth 501 has a pleth period 571 inversely related to pulse rate (PR). Under some circumstances, an individual's respiration modulates the shape of each pleth pulse. This modulation may be described in terms of a predefined pleth feature or “shape metric.” In an advantageous embodiment, a shape metric is defined by a difference or “error” E 572 between the diastolic portion of a pleth pulse and its corresponding triangular pulse approximation, normalized by the area A 573 under the triangular pulse approximation.
[0050] As shown in FIG. 5C , a respiration-modulated shape metric 522 has a cyclical period 581 inversely related to respiration rate (RR). As shown in FIG. 5D , a spectrum 502 of the modulated shape metric 522 includes a respiration rate (RR) peak 591.
[0051] A SM processor 500 is described above as based upon a normalized diastolic error metric (E/A). In other embodiments, shape metrics may be based upon other pulse features such as a diastolic area, error or angle normalized by the corresponding systolic area, error or angle (Ad/As, Ed/Es, θd/θs), or shape metrics may be related to the arc length of the diastolic and/or systolic portions of a pleth pulse, to name a few. These and other pulse shapes and features responsive to respiration are also contemplated herein.
[0052] FIGS. 6A-B further illustrates pulse shape features that are derived by a feature extractor 520 (FIG. 5A ) embodiment. Acceptable pleth pulses 610 are generated by the pre-processor 200 (FIG. 2A ), as described above. For convenience of illustration, the inverse of an “intensity” pulse is shown, as described with respect to FIGS. 15A-B , below. The pleth pulse 610 has a peak Y at a time W and corresponding valleys at times X and Z. The peak and valleys define a triangular pulse 620 XYZ that approximates the pleth pulse 610. Further, the time line WY corresponding to the peak Y divides the pleth pulse 610 into a systolic portion 630 and a diastolic portion 640.
[0053] As shown in FIG. 6A , a systolic error Es 631 is defined as the total area between the pleth pulse 610 and the approximate triangular pulse 620 within the systolic portion 630. A diastolic error Ed 641 is defined as the total area between the pleth pulse 610 and the triangular pulse 620 within the diastolic portion 640.
[0054] As shown in FIG. 6B , a systolic area As 632 is defined as the total area under the triangular pulse 620 within the systolic portion 630. A diastolic area Ad 642 is defined as the total area under the triangular pulse 620 within the diastolic portion 640. A systolic angle θs 633 is defined as the angle XYW defined by the triangular pulse within the systolic portion 630. A diastolic angle θd 643 is defined as the angle ZYW defined by the triangular pulse within the diastolic portion 640.
[0055] Based upon the above-described pulse feature definitions, normalized pulse features may be defined. These may include normalized diastolic pulse features, such as Ed/Ad, corresponding to the diastolic triangular pulse error normalized by the diastolic triangular pulse area. Other normalized diastolic pulse features may include a diastolic area, error or angle normalized by the corresponding systolic area, error or angle (Ad/As, Ed/Es, θd/θs).
[0056] FIGS. 7A-B illustrate additional pulse shape features. As shown in FIG. 7A , pulse features may be based upon the length of a curve (trace, arc, path or line) portion of a pleth pulse 710. In particular, a diastolic curve length Ld 745 between the pulse peak Y and valley Z is defined in polar coordinates as:
[0057]
where r is the distance from W (time corresponding to the peak Y) to any point V along the curve 710 and θ is the angle between r and the time axis WZ. Ld 745 may be similarly defined in Cartesian coordinates. A systolic curve length Ls 735 may be defined in similar fashion. A normalized length pulse feature Ld/Ls may be defined accordingly. In other embodiments, pulse features Ld 745 or Ls 735 may be normalized by the diastolic 640 or systolic 630 areas or angles defined with respect toFIG. 6B , above. In various embodiments, pulse features Ld 745 or Ls 735 also may be normalized by pulse height WY, by diastolic WZ or systolic XW pulse widths, by total pulse width XZ or by mathematical combinations of these measures of pulse height and pulse width to name a few.
where r is the distance from W (time corresponding to the peak Y) to any point V along the curve 710 and θ is the angle between r and the time axis WZ. Ld 745 may be similarly defined in Cartesian coordinates. A systolic curve length Ls 735 may be defined in similar fashion. A normalized length pulse feature Ld/Ls may be defined accordingly. In other embodiments, pulse features Ld 745 or Ls 735 may be normalized by the diastolic 640 or systolic 630 areas or angles defined with respect to
[0058] As shown in FIG. 7B , pulse shape features may be based upon the curvature of a portion of a pleth pulse 710. In particular, a curvature κ is defined in pedal coordinates as:
[0059]
where the pedal coordinates of a point V with respect to the pulse 710 and the pedal point W are the radial distance r from W to V and the perpendicular distance p from W to the line t tangent to the pulse 710 at V, as shown. κ may be similarly defined in Cartesian or polar coordinates. Total curvature K of a curve segment between points a and b is then
where the pedal coordinates of a point V with respect to the pulse 710 and the pedal point W are the radial distance r from W to V and the perpendicular distance p from W to the line t tangent to the pulse 710 at V, as shown. κ may be similarly defined in Cartesian or polar coordinates. Total curvature K of a curve segment between points a and b is then
[0060]
A diastolic curvature Kd 746 or systolic curvature Ks 736 pulse shape feature may be defined accordingly. In other embodiments, a curvature pulse shape feature may be defined according to the absolute value of the maximum and/or minimum curvature of the pulse 710 or pulse segment 730, 740, or the curvature of a particular feature, such as a dicrotic notch. In other embodiments, pulse shape features Kd 746 or Ks 736 may be normalized by the diastolic 640 or systolic 630 areas or angles defined above with respect toFIGS. 6A-B . In various embodiments, pulse features Kd 746 or Ks 736 also may be normalized by pulse height WY, by diastolic WZ or systolic XW pulse widths, by total pulse width XZ or by mathematical combinations of these measures of pulse height and pulse width to name a few. In other embodiments, various normalized systolic and/or diastolic pulse features may be similarly defined.
A diastolic curvature Kd 746 or systolic curvature Ks 736 pulse shape feature may be defined accordingly. In other embodiments, a curvature pulse shape feature may be defined according to the absolute value of the maximum and/or minimum curvature of the pulse 710 or pulse segment 730, 740, or the curvature of a particular feature, such as a dicrotic notch. In other embodiments, pulse shape features Kd 746 or Ks 736 may be normalized by the diastolic 640 or systolic 630 areas or angles defined above with respect to
[0061] FIG. 8A-D illustrate an FM processor 800 that derives an “FM” spectrum Ffm 802 responsive to a respiration-induced frequency modulation of the pleth. As shown in FIG. 8A , the FM processor 800 has a conditioned pleth 112 input and generates a corresponding FM spectrum Ffm 802 that is responsive to a demodulated pleth 822. In an embodiment, the demodulator 820 utilizes a metric Δ responsive to the time difference between identifiable epochs of each pleth pulse. In an embodiment, the epochs are based upon a dicrotic notch. In an embodiment, the metric Δ is the time difference between two identifiable portions of a dicrotic notch such as the notch local maximum, local minimum, or mid-point between local maximum and local minimum, to name a few.
-
- [0062] As shown in
FIG. 8B , a pleth 801 has a pleth period 871 inversely related to pulse rate (PR). Under certain conditions, an individual's respiration frequency modulates (FM) the plethysmograph 801. In particular, the modulation period 881 (FIG. 8C ) is inversely related to respiration rate (RR).FIG. 8C illustrates a respiration-modulated FM metric 822 over time. In particular, an FM metric 822, such as the metric Δ described above, has a cyclical period 881 inversely related to respiration rate (RR). As shown inFIG. 8D , a spectrum 802 of the FM metric 822 includes a respiration rate (RR) peak 891.
- [0062] As shown in
[0063] FIG. 9 illustrates another pre-processor 900 embodiment having a pleth 101 input and generating a windowed features 962 output. The pre-processor 900 has a candidate pulse processor 220 and pulse modeler 230 that operate on the pleth 101 input so as to generate an acceptable pulses 232 output, as described with respect to FIG. 2A , above. Further, the pre-processor 900 has a time base standard 940, a feature extractor/normalizer 950, and a windowing/outlier rejecter 960. The time base standard 940 inputs acceptable pulses 941 and outputs resized pulses 942. In particular, the time base standard 940 mathematically re-samples the input pulses 941 so that each pulse has the same number of samples. For example, if a standard pulse has 50 samples and an input pulse 941 has 60 samples, then the input pulse 941 sample interval is made larger by 60/50 or 1.2 times so that the resized input pulse width is 50 samples. Similarly, if an input pulse 941 has 40 samples, then the input pulse 941 sample interval is made smaller by 40/50 or 0.8 times so that the resized input pulse width is 50 samples. A resized input pulse is derived by interpolating the original pulse at re-sampled points. For example, a linear interpolation embodiment is used according to the following
[0064]
where x2−x1 is the original sample interval; y1 and y2 are input pulse 401 values at x1 and x2, respectively; x is a resized sample point between x1 and x2 and y is the resized pulse value at x. In other embodiments, the interpolation is a cubic spline or a polynomial interpolation to name a few.
where x2−x1 is the original sample interval; y1 and y2 are input pulse 401 values at x1 and x2, respectively; x is a resized sample point between x1 and x2 and y is the resized pulse value at x. In other embodiments, the interpolation is a cubic spline or a polynomial interpolation to name a few.
[0065] Also shown in FIG. 9 , the feature extractor/normalizer 950 inputs the resized pulses 942 described above and outputs normalized pulse features 952. Pulse features may include one or more of the differences or “errors” E between an acceptable pulse and its corresponding triangular pulse; areas A under the triangular pulse; and apex angles θ of a triangular pulse, to name a few, as described in detail with respect to FIGS. 6-7 , above. Pulse features may also distinguish between a steeper-slope portion corresponding to systole S and a shallower-slope portion corresponding to diastole D. Pulse features are normalized by comparing one or more extracted features with one or more other extracted features. In an embodiment, normalized pulse features 952 advantageously include Ed/Ad corresponding to the diastolic triangular pulse error normalized by the diastolic triangular pulse area. Other normalized pulse features 952 may include a diastolic area, error or angle normalized by the corresponding systolic area, error or angle (Ad/As, Ed/Es, θd/θs). These and additional normalized pulse features relating to an acceptable pulse and/or its corresponding triangular pulse are also contemplated herein and described with respect to FIGS. 6-7 , above.
[0066] Further shown in FIG. 9 , the windowing/outlier rejecter 960 inputs the normalized features 952 and outputs windowed features 962. The windowed features 962, in turn, may be frequency transformed or analyzed in the time domain to determine a respiration modulation of the features, as described above. In particular, windowing 960 defines a sample size (window size) of the normalized features 952. The outlier rejector 960 calculates a mean or median of the normalized features 952 falling within the window, defines an acceptable range around the mean or median and rejects normalized features falling outside of that acceptable range.
[0067] Window size may be a function of a respiration rate (RR) 964, a heart rate (HR) 966 or both. In particular, HR 966 corresponds to the input pulse 101 frequency and hence determines the time between samples of the normalized features 952. RR 964 corresponds to the number of feature cycles within a window and hence sets a lower limit on the window size in order to resolve the frequency of those feature cycles.
[0068] Pulse rates may typically vary from a resting rate of 40-60 BPM for athletes to 60-90 BPM for non-athletes. Maximum heart rates are typically defined as 220—age. Hence, pulse rates might typically range from 50 to 200 BPM, which is a 4:1 variation in time between samples (0.3 sec to 1.2 sec). Respiration rates may typically vary between 12-20 breaths per minute for resting adults to 35-45 breaths per minute for exercising adults. Hence RR may typically range from 10-50 breaths per minute, which is a 5:1 variation in the number of respiration cycles per window. Accordingly, the number of pulse feature samples per respiration cycle may have a 20:1 variation.
[0069] Windowing 960 may be fixed or adjustable. Further, successive windows may be overlapping, i.e. a sliding window may be used, or may be adjacent and non-overlapping. A typical window size may range, say, between 15-120 sec. or more. Accordingly, a window size may encompass, say, 20 respiration cycles at 10 breaths per minute over a 120 sec. window to 12 respiration cycles at 50 breaths per minute over a 15 sec. window. In an embodiment, the window size is adaptively adjusted based upon detected RR and PR.
[0070] FIG. 10 illustrates a plethysmographic respiration processor 1000 embodiment having a conditioned plethysmograph waveform (pleth) 112 input and a smoothed respiration rate (RRs) 1005 output. The respiration processor 1000 includes parallel processors 1020, decision logic 1100-1300 and a smoother 1030. The conditioned pleth 112 contains pleth sections corresponding to sliding acceptable windows designated by the pre-processor 200 (FIG. 2A ), as described above with respect to FIGS. 2A-B . The parallel processors 1020 each operate on conditioned pleth 112 so as to generate frequency spectrums 1022 responsive to respiration rate. The parallel processors 1020 include a baseline processor 300, an amplitude modulation (AM) processor 400, a high pass filtered (HPF) shape modulation (SM) processor 500 and a SM processor 501. In particular, the baseline processor 300 derives a “baseline” spectrum Fb 302 responsive to a respiration-induced baseline shift in a pleth. The baseline processor 300 is described in detail with respect to FIGS. 3A-C , above. The AM processor 400 derives an “AM” spectrum Fam 402 responsive to a respiration-induced amplitude modulation of the pleth. The AM processor 400 is described in detail with respect to FIGS. 4A-D , above. The SM processors 500, 501 derive “SM” spectrums Fs 502, Fs′ 504 each responsive to a respiration-induced shape modulation of the pleth. The SM processors 500, 501 are described in detail with respect to FIGS. 5-7 , above.
[0071] As described above, the processors 1020 each generate one spectrum 1022 for each sliding window of the conditioned pleth 112. Accordingly, the decision logic 1100-1300 attempts to generate a respiration rate (RR) value for each conditioned pleth 112 window. The decision logic 1100-1300 compares two or more of the spectrums Fb, Fam, Fs and Fs′ 422 so as to calculate a respiration rate (RR) 1004. If the decision logic 1100-1300 cannot determine a RR 1004 value from the spectrums 1022, the corresponding conditioned pleth window 112, is rejected. A smoother 1030 generates a smoothed respiration rate 1005 calculated over multiple respiration rate 1004 values. In an embodiment, the smoother 1030 determines the median value of RR 1004 corresponding to multiple ones of the conditioned pleth windows 112. In an embodiment, the median value is calculated over five conditioned pleth windows 112. The decision logic 1100-1300 is described in detail with respect to FIGS. 11-13 , below.
[0072] FIGS. 11A-C illustrate the output of the baseline processor 300 (FIG. 10 ), AM processor 400 (FIG. 10 ) and SM processor 500 (FIG. 10 ), respectively, assuming that a conditioned pleth 112 (FIG. 10 ) exhibits each of a baseline shift, an amplitude modulation and a shape modulation due to respiration. As shown in FIG. 11A , in view of both a respiration-induced baseline shift and AM modulation, the windowed pleth spectrum 1110 is a combination of a baseline shift spectrum 302 (FIG. 3C ) and an AM spectrum 402 (FIG. 4D ). This combination is also the baseline spectrum Fb 302 (FIG. 3A ), i.e. the frequency transform of the conditioned pleth 112. Hence, in this example, the baseline spectrum 1110 has two possible local maximums or “peaks” 1115, 1116. One peak is due to respiration shifting the pleth baseline and one peak is due to respiration amplitude modulating the pleth. However, these peaks cannot be distinguished. In particular, if RR<0.5PR, then peak 1115 is at a frequency corresponding to RR and peak 1116 is at a frequency corresponding to PR-RR. Likewise, if RR is >0.5 PR, then peak 1115 is at a frequency corresponding to PR-RR and peak 1116 is at a frequency corresponding to RR. That is, “twin” peaks 1115, 1116 occur symmetrically on either side of frequency ½ PR, one at frequency RR and one at frequency PR-RR, but the peak corresponding to the respiration rate RR cannot be resolved by the baseline processor 302 (FIG. 10 ) alone.
[0073] As shown in FIG. 11B , in view of both a respiration-induced baseline shift and AM modulation, the AM spectrum Fam 402 (FIG. 10 ) is a combination of the spectrums of FIG. 3C and FIG. 4C after demodulation. Hence, in this example, the AM processor output 402 (FIG. 10 ) has two possible local maximums or peaks 1125, 1126. One peak is due to demodulating the pleth corresponding to the spectrum of FIG. 4C , resulting in the spectrum of FIG. 4D . The other peak is due to demodulating the pleth corresponding to the spectrum of FIG. 3C , which translates the pleth fundamental 392 (FIG. 3C ) at PR to DC and the respiration-related peak 391 (FIG. 3C ) to PR-RR. As with the peaks described with respect to FIG. 11A , these “twin” peaks 1125, 1126 occur symmetrically on either side of ½PR, but the peak corresponding to the respiration rate RR cannot be resolved by the AM processor 400 (FIG. 10 ) alone.
[0074] As shown in FIG. 11C , the SM spectrum Fs 502 is unaffected by either a baseline shift or by amplitude modulation. In particular, a respiration-induced baseline shift, which shifts the entire pleth waveform up or down, has negligible effect on the error E 572 (FIG. 5B ) or the triangular area A 573 (FIG. 5B ). Further, although respiration-induced AM increases or decreases the pleth amplitude, this is accounted for by normalizing the error E by the triangular area A. As such, in view of both a respiration-induced baseline shift and AM, the SM spectrum Fs 502 is responsive only to shape modulation, as shown in FIG. 5D , i.e. a single local maximum or peak 1135 occurs at the respiration rate.
[0075] As shown in FIGS. 11A-C , ideally respiration rate may be determined by first verifying the existence of twin peaks 1115, 1116 symmetric about 0.5PR in the baseline spectrum 1110 and twin peaks about 0.5PR in the AM spectrum 1120. Second, one twin from each spectrum 1110, 1120 is matched with the single peak in the SM spectrum 1130. For example, a match between peaks 1115 (FIG. 11A ), 1125 (FIG. 11B ) and 1135 (FIG. 11C ) would provide a robust indication of RR. However, pleths from various sensors, monitors and patients may yield spectrums with erroneous peaks due to physiological conditions or artifact. Accordingly, various peaks and matching conditions are utilized by the decision logic to determine RR, as described with respect to FIGS. 12-13 , below.
[0076] As shown in FIG. 11D , a peak identifying nomenclature 1140 is used in describing decision logic with respect to the baseline spectrum Fb 302 (FIG. 10 ) and the AM spectrum Fam 402 (FIG. 10 ). The largest peak in a spectrum is designated {circle around (1)} and its twin designated {circle around (4)}. If the largest peak is the first peak, which is sometimes erroneous, then the second largest peak is designated {circle around (2)} and its twin designated {circle around (5)}. If the largest peak is the last peak, which is also sometimes erroneous, the second largest peak is designated {circle around (3)} and its twin designated {circle around (6)}.
[0077] FIG. 12 illustrates the decision logic 1200 for advantageously deriving a robust value for respiration rate based upon each of the baseline 300, AM 400 and SM 500 processors (FIG. 10 ) operating on a conditioned pleth 112 (FIG. 10 ). The spectrums Fb, Fam and Fs from these processors are input 1210 into the decision logic 1200. A peak detector 1220 locates the largest peak {circle around (1)} and its twin {circle around (4)} from each of Fb 1110 (FIG. 11A ) and Fam 1120 (FIG. 11B ) and the largest peak {circle around (1)} from Fs 1130 (FIG. 11C ). The comparator 1230 looks for a three-way match from, say, the largest peak from each of the spectrums. This comparison is denoted 1-1-1, designating the largest peaks from the spectrums Fb-Fam-Fs, respectively. If the frequencies of all of these peaks match 1240, within a predetermined error, then that frequency is output as the respiration rate 1250 for that conditioned pleth window 112 (FIG. 10 ). If there is no match 1240, other combinations 1260, 1266 of peaks of a particular series are compared 1230, such as the largest peak from Fb, the twin to the largest peak from Fam and the largest peak from Fs, denoted 1-4-1. Hence, all of the following combinations are denoted the first series of combinations to try, i.e. series I: 1-1-1; 1-4-1; 4-1-1; 4-4-1.
[0078] As shown in FIG. 12 , if there are no matches from series I, other series 1270, 1275 having different types of combinations are tried, as explained below. If a particular twin cannot be located, the corresponding series is rejected 1275. If no 3-way matching peaks are found after trying all combinations in each of series I, II, III, IV 1270, then that particular window is rejected 1280 and no respiration rate value is determined that corresponds to that window.
[0079] Series II represents a second set of peak comparisons. In some cases, the largest peak {circle around (1)} from Fb or Fam or both may be the first peak, which is often erroneous. As such, comparisons may be made using the second largest peaks {circle around (2)} from Fb and Fm and the corresponding twins {circle around (5)}. The twins in this series are verified to exist, but not used. Accordingly, in an embodiment, the largest peaks {circle around (1)} and the second largest peaks {circle around (2)} are compared in the following combinations: 2-1-1; 1-2-1; 2-2-1.
[0080] Series III represents a third set of peak comparisons. In some cases, the largest peak from Fb or Fam or both may be the last peak, which is also often erroneous. As such, comparisons may be made using the second largest peaks {circle around (3)} from Fb and Fam and the corresponding twins {circle around (6)}. Accordingly, in an embodiment, these peaks are compared in the following combinations: 3-3-1; 6-3-1; 3-6-1; 6-6-1.
[0081] Series IV represents yet another set of peak comparisons. In some cases, the largest peak from Fs is erroneous. Hence, comparisons may be made using the largest peak from Fs′, designated {circle around (3)}, and the largest peak and corresponding twin from Fb and Fam, designated {circle around (1)} and {circle around (4)}, as noted above. Accordingly, in an embodiment, these peaks are compared with each other in the following combinations: 4-4-3; 4-1-3; 1-4-3; 1-1-3. In other embodiments, other combinations are possible, for example, the twins to the second largest peaks from Fb and Fam, which are designated {circle around (5)}, could be used in various combinations with other designated peaks described above. If all combinations fail to yield a three-way match 1240, then that particular window is rejected 1280.
[0082] FIG. 13 illustrates decision logic 1300 for advantageously deriving a robust value for respiration rate based upon a two-way match of the spectrums Fb, Fam and Fs (or Fs′) from each of the baseline 300, AM 400 and shape 500, 501 processors (FIG. 10 ) plus an additional condition 1390. In an embodiment, decision logic 1300 is used in the event a respiration rate RR 1004 (FIG. 10 ) cannot be derived from a three-way match of the spectrums Fb, Fam and Fs (or Fs′), as described with respect to FIG. 12 , above.
[0083] As shown in FIG. 13 , in a series V, the largest peaks from Fb and Fs, denoted 1_1 (without utilizing Fam) are compared for a two-way match 1330. If there is a match, an additional condition 1370 must be met. In an embodiment, the condition 1390 is that the matching frequencies of Fb and Fs must be within a predetermined difference of the smoothed respiration rate (RRs) 1005 (FIG. 10 ). In an embodiment, the predetermined difference is 1 bpm. If so, the matching frequencies are output as the respiration rate RR 1380. If not, the largest peaks from Fam and Fs, denoted _11 (without utilizing Fb) are also compared for a match 1330. If there is a match from this comparison and the additional condition 1370 is met, then the matching frequencies are output as the respiration rate RR 1380. If these combinations are compared without a match 1350, then a series VI is utilized.
[0084] Also shown in FIG. 13 , in a series VI, the various peaks from Fb and Fam, each denote 1-6, are compared for a two-way match 1330. If there is a match, the additional condition 1370 must be met. If all combinations, e.g. 11, 12, 13 . . . 21, 22, 23 . . . 36, 46, 56 are tried without a match or there is a match but the additional condition is not met, the window is rejected 1360. In other embodiments, other peaks are compared 1330 and other conditions 1390 must be met.
[0085] FIG. 14 illustrates a physiological monitoring system 1400 that incorporates a plethysmographic respiration processor 100 (FIG. 1 ), as described above. The monitoring system 1400 has a monitor 1410, an optical sensor 1420 and an interconnect cable 1430 connecting the monitor 1410 and sensor 1420. The monitoring system 1400 generates physiological parameters that indicate one or more aspects of a person's physical condition, including, advantageously, a plethysmograph-derived respiration rate. The sensor 1420 attaches to a tissue site 10, such as a fingertip, and is capable of irradiating the tissue site 10 with differing wavelengths of light and detecting the light after attenuation by pulsatile blood flow within the tissue site 10. The monitor 1410 communicates with the sensor 1420 via the interconnect cable 1430 to receive one or more detected intensity signals and to derive from those intensity signals one or more physiological parameters. The monitor also has a display 1412 for presenting parameter values, including respiration rate (RR). Controls 1415 set alarm limits, processing modes, display formats and more. An audio transducer 1416 provides alarm sounds, pulse beeps and button press feedback to name a few. Indicators 1418 show monitor status. The display 1412 may include readouts, colored lights or graphics generated by LEDs, LCDs or CRTs to name a few and is capable of displaying indicia representative of calculated physiological parameters, including respiration rate, and waveforms, including plethysmographs. The display 1412 is also capable of showing historical or trending data related to one or more of the measured parameters or combinations of the measured parameters. User I/O may include, for example, push buttons 1415 and indicators 1418. The push buttons may be soft keys with display-indicated functions or dedicated function keys 1415. Other user I/O (not shown) may include keypads, touch screens, pointing devices, voice recognition devices and the like.
[0086] FIG. 15A illustrates a light absorption waveform 1501 at an illuminated peripheral tissue site corresponding to a pulsatile blood volume at that site. The peripheral tissue site is illuminated by, and the corresponding absorption is (indirectly) measured by, an optical sensor 1420 (FIG. 14 ), as described above. A y-axis 1530 represents the total amount of light absorbed by the tissue site, with time shown along an x-axis 1540. The total absorption is represented by layers, including the static absorption layers due to tissue 1532, venous blood 1534 and a baseline of arterial blood 1536. Also shown is a variable absorption layer 1538 due to the pulse-added volume of arterial blood that is used to derive a plethysmograph, as described above and further with respect to FIG. 15B , below. This light absorption waveform 1501 varies as a function of the wavelength of the optical sensor emitted light according to the blood constituency. Indeed, it is this wavelength variation that allows a multi-parameter patient monitor to determine blood hemoglobin components and other blood constituents along with respiration rate characteristics, as described above.
[0087] As shown in FIG. 15A , a pulsatile blood volume 1538 is a function of heart stroke volume, pressure gradient, arterial elasticity and peripheral resistance. The ideal pulsatile blood volume waveform displays a broad peripheral flow curve, with a short, steep inflow phase 1516 followed by a 3 to 4 times longer outflow phase 1518. The inflow phase 1516 is the result of tissue distention by the rapid blood volume inflow during ventricular systole. During the outflow phase 1518, blood flow continues into the vascular bed during diastole. The end diastolic baseline 1514 indicates the minimum basal tissue perfusion. During the outflow phase 1518 is a dicrotic notch 1515. Classically, the dicrotic notch 1515 is attributed to closure of the aortic valve at the end of ventricular systole. However, it is also a function of reflection from the periphery of an initial, fast propagating pressure pulse that occurs upon the opening of the aortic valve preceding the arterial flow wave. Pulsatile blood volume varies with physiological properties such as heart stroke, vessel size, elasticity and vascularization, to name a few. Accordingly, the blood flow waveform shape can vary significantly from individual to individual and between tissue sites.
[0088] FIG. 15B illustrates a plethysmograph waveform 1502 detected by an optical sensor 1420 (FIG. 14 ). In particular, detected intensity is shown along the y-axis 1550 versus time shown along the x-axis 1560. The plethysmograph waveform 1502 is a time series of plethysmograph (“pleth”) pulses and relates to the time-varying pulsatile blood volume 1538 (FIG. 15A ) measured at a particular location on a person, referred to herein as a “tissue site.” A tissue site can be a fingertip, ear lobe, toe, nose or forehead to name just as few. A person is used herein as the referenced subject of optical sensor measurements, but other living species also have a measurable pleth and are included within the scope of this disclosure.
[0089] As shown in FIG. 15B , an optical sensor 1420 (FIG. 14 ) does not directly detect absorption and, hence, does not directly measure the volume waveform 1538 (FIG. 15A ). However, the plethysmograph waveform 1502 is merely an out-of-phase version of the volume profile 1538. Stated differently, the plethysmograph waveform 1502 varies inversely with the pulsatile blood volume 1538. In particular, the peak detected intensity 1554 occurs at minimum volume 1514 and the minimum detected intensity 1552 occurs at maximum volume 1512. Further, a rapid rise in volume during the inflow phase 1516 is reflected in a rapid decline in intensity 1556; and the gradual decline in volume during the outflow phase 1518 is reflected in a gradual increase 1558 in detected intensity. The intensity waveform 1502 also displays a dicrotic notch 1555.
[0090] FIG. 16 further illustrates a physiological monitoring system 1600 having an optical sensor 1620 attached to a tissue site 10, a monitor 1610 and an interconnecting sensor cable 1620. The sensor 1620 has emitters 1622, each of which transmit light of a specified wavelength. Drivers 1654, 1655 convert digital control signals into analog drive signals capable of activating the emitters 1622. A front-end 1652, 1653 converts composite analog intensity signal(s) from the detector(s) 1624 into digital data input to a digital signal processor (DSP) 1658. The DSP 1658 may comprise any of a wide variety of data and/or signal processors capable of executing programs for determining physiological parameters from input data. In an embodiment, the DSP executes firmware 1659 including pre-processors, respiration processors and post processors, such as described with respect to FIGS. 1-13 , above.
[0091] Also shown in FIG. 16 , an instrument manager 1682 may comprise one or more microcontrollers controlling system management, such as monitoring the activity of the DSP 1658. The instrument manager 1682 has an interface port 1683 for monitor communications. In an embodiment, the interface port 1683 has a display driver, an audio driver, user inputs and I/O for driving displays and alarms, responding to buttons and keypads and providing external device input/output communications. In an embodiment, the displays can indicate a variety of physiological parameters 1686 such as respiration rate (RR), pulse rate (PR), plethysmograph (pleth), perfusion index (PI), pleth variability index (PVI), signal quality (IQ) and values for blood constituents including oxygen saturation (SpO2), carboxyhemoglobin (HbCO), methemoglobin (HbMet), total hemoglobin (Hbt) and oxygen content (0C) as well as instrument and sensor status, such as sensor life, to name but a few.
[0092] FIG. 17 illustrates a demodulator 1700 having a modulated/multiplexed detector signal 1703 input and demodulated signal 1705 outputs. That is, the demodulator input 1703 is the result of a detector 1624 (FIG. 16 ) response to N emitter wavelengths 1622 (FIG. 16 ) that are cyclically turned on and off by emitter drivers 1654 (FIG. 16 ) so as to illuminate a tissue site with multiple wavelength optical radiation, as is well known in the pulse oximetry art. The digitized detector signal 1703 corresponds to the ND converter 1657 (FIG. 16 ) input to the DSP 1658 (FIG. 16 ). The DSP has demodulator 1700 (preprocessor) firmware 1659 which generates N channels of demodulated signals r1(t), r2(t), . . . , rN(t) 1705 in response. One signal ri(t) corresponding to each emitter wavelength 1622. These demodulated signals are plethysmographs, as described above.
[0093] The demodulator 1700 has mixers 1730 and low pass filters 1740 for each channel and demodulating signals di(t) 1704 provided to each mixer 1730. The demodulating signals are linear combinations of (orthogonal) basis functions of the form
[0094]
which are derived by approximating the optical response of the emitters to on/off periods of the emitter drivers. M is the number of basis functions needed to approximate such optical responses. φj(t) is the jth basis function used by the demodulator. In one embodiment, the basis functions are of the form
which are derived by approximating the optical response of the emitters to on/off periods of the emitter drivers. M is the number of basis functions needed to approximate such optical responses. φj(t) is the jth basis function used by the demodulator. In one embodiment, the basis functions are of the form
[0095]
where T is the period of the repeating on/off patterns of the emitter drivers. Accordingly, the lowpass filter outputs 1705 are r1(t), r2(t), . . . , rN(t), which are estimates of absorption for each emitter wavelength in view of noise n(t) that is additive to each channel. Plethysmograph demodulators are described in U.S. Pat. No. 5,919,134 titled Method and Apparatus for Demodulating Signals in a Pulse Oximetry System, issued Jul. 6, 1999; U.S. Pat. No. 7,003,338 titled Method and Apparatus for Reducing Coupling Between Signals, issued Feb. 21, 2006; and U.S. patent application Ser. No. 13/037,321 titled Plethysmograph Filter, filed Feb. 28, 2011; all assigned to Masimo Corporation and incorporated by reference herein.
where T is the period of the repeating on/off patterns of the emitter drivers. Accordingly, the lowpass filter outputs 1705 are r1(t), r2(t), . . . , rN(t), which are estimates of absorption for each emitter wavelength in view of noise n(t) that is additive to each channel. Plethysmograph demodulators are described in U.S. Pat. No. 5,919,134 titled Method and Apparatus for Demodulating Signals in a Pulse Oximetry System, issued Jul. 6, 1999; U.S. Pat. No. 7,003,338 titled Method and Apparatus for Reducing Coupling Between Signals, issued Feb. 21, 2006; and U.S. patent application Ser. No. 13/037,321 titled Plethysmograph Filter, filed Feb. 28, 2011; all assigned to Masimo Corporation and incorporated by reference herein.
[0096] Advantageously, a plethysmographic respiration processor 100 (FIG. 1 ) is implemented on an advanced pulse oximetry monitor or an advanced blood parameter monitor, as described above. Although a plethysmographic respiration processor is described above with respect to deriving respiration rate from a plethysmograph waveform, in other embodiments, a plethysmographic respiration processor may be used to derive other respiration-related parameters. In a particularly advantageous embodiment, a plethysmographic respiration processor is used in conjunction with an acoustic monitor or combined blood parameter and acoustic monitor so as to improve the accuracy of, robustness of, or otherwise supplement acoustic-derived respiration rate measurements or other acoustic-derived respiration parameters.
[0097] A plethysmographic respiration processor has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims herein. One of ordinary skill in art will appreciate many variations and modifications.
Claims
What is claimed is:
1. A plethysmographic respiration detector responsive to respiratory effects appearing on a detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of respiration rate, the plethysmographic respiration detector comprising:
a preprocessor configured to identify a portion of a plethysmograph waveform which includes a physiologically acceptable series of plethysmograph waveform pulses;
one or more processors configured to use a plurality of different techniques to derive a plurality of different frequency spectrums using the portion of the plethysmograph waveform, each of the plurality of different frequency spectrums responsive to at least one respiratory effect on the portion of the plethysmograph waveform and including a plurality of local maximums, the one or more processors comprising at least two of:
a baseline processor configured to receive the portion of the plethysmograph waveform and output a baseline frequency spectrum responsive to a respiratory-induced baseline shift of the portion of the plethysmograph waveform,
an amplitude modulation (AM) processor configured to receive the portion of the plethysmograph waveform and output an AM frequency spectrum responsive to a respiratory-induced amplitude modulation of the portion of the plethysmograph waveform, and
a shape modulation (SM) processor configured to receive the portion of the plethysmograph waveform and output a SM frequency spectrum responsive to a respiratory-induced shape modulation of the portion of the plethysmograph waveform,
wherein a first frequency spectrum of the plurality of different frequency spectrums is one of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum, and a second frequency spectrum of the plurality of different frequency spectrums is different from the first frequency spectrum and is one of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum; and
a decision logic configured to determine a respiration rate based at least on a comparison of one or more local maximums of the first frequency spectrum and one or more local maximums of the second frequency spectrum, the decision logic comprising:
a peak detector configured to operate on at least two of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum so as to determine the local maximums of the at least two of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum, and
a comparator configured to determine if the local maximums of the at least two of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum occur at matching frequencies within a first tolerance,
wherein the decision logic is configured to generate a respiration rate output if the comparator finds at least one local maximum of each of the at least two of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum occur at matching frequencies within the first tolerance.
2. The plethysmographic respiration detector according to claim 1 wherein the decision logic is configured to determine the respiration rate a plurality of times over portions of the plethysmograph waveform to generate a plurality of respiration rate outputs, and further comprising a smoother configured to operate on the plurality of the respiration rate outputs so as to derive a smoothed respiration rate output.
3. The plethysmographic respiration detector according to claim 2 wherein the decision logic is further configured to reject an additional respiration rate if it differs from the smoothed respiration rate output by more than a first amount.
4. The plethysmographic respiration detector according to claim 1 wherein the respiration rate comprises a frequency of one of the local maximums of the first frequency spectrum.
5. The plethysmographic respiration detector according to claim 1 wherein the peak detector is configured to identify frequencies of the local maximums of the first frequency spectrum relative to a frequency corresponding to a pulse rate, and the comparator is configured to determine if the local maximums of the first frequency spectrum and the second frequency spectrum occur at matching frequencies within the first tolerance by comparing individual local maximums of the first frequency spectrum and individual local maximums of the second frequency spectrum in an order based at least on the identified frequencies of the local maximums of the first frequency spectrum relative to the frequency corresponding to the pulse rate.
6. The plethysmographic respiration detector according to claim 1 wherein the comparator is configured to determine if the local maximums of the first frequency spectrum and the second frequency spectrum occur at matching frequencies within the first tolerance by comparing individual local maximums of the first frequency spectrum and individual local maximums of the second frequency spectrum in an order based at least on magnitudes of the local maximums of the first frequency spectrum.
7. The plethysmographic respiration detector according to claim 1 wherein the comparator is configured to compare the local maximums of the first frequency spectrum and the second frequency spectrum until: (1) the comparator determines that one local maximum of the first frequency spectrum and one local maximum of the second frequency spectrum occur at matching frequencies within the first tolerance; or (2) the comparator compares at least two of the local maximums of the first frequency spectrum and at least two of the local maximums of the second frequency spectrum and determines that none of the at least two of the local maximums of the first frequency spectrum and none of the at least two of the local maximums of the second frequency spectrum occur at matching frequencies within the first tolerance.
8. The plethysmographic respiration detector according to claim 7 wherein the decision logic is configured to determine no respiration rate if the comparator compares the at least two of the local maximums of the first frequency spectrum and the at least two of the local maximums of the second frequency spectrum and determines that none of the at least two of the local maximums of the first frequency spectrum and none of the at least two of the local maximums of the second frequency spectrum occur at matching frequencies within the first tolerance.
9. The plethysmographic respiration detector according to claim 1 wherein the one or more processors comprises the baseline processor, the baseline processor comprising:
a first signal conditioner configured to generate a first conditioned pleth from the portion of the plethysmograph waveform; and
a first frequency transform configured to receive the first conditioned pleth and generate the baseline frequency spectrum,
wherein the first frequency spectrum is the baseline frequency spectrum.
10. The plethysmographic respiration detector according to claim 1 wherein the one or more processors comprises the AM processor, the AM processor comprising:
a second signal conditioner configured to generate a second conditioned pleth from the portion of the plethysmograph waveform;
a demodulator configured to demodulate the second conditioned pleth to generate a demodulated pleth; and
a second frequency transform configured to receive the demodulated pleth and generate the AM frequency spectrum,
wherein the first frequency spectrum is the AM frequency spectrum.
11. The plethysmographic respiration detector according to claim 1 wherein the one or more processors comprises the SM processor, the SM processor comprising:
a third signal conditioner configured to generate a third conditioned pleth from the portion of the plethysmograph waveform;
a feature extractor configured to generate a modulated metric from the third conditioned pleth; and
a third frequency transform configured to generate the SM frequency spectrum based at least on the modulated metric,
wherein the first frequency spectrum is the SM frequency spectrum.
12. A plethysmographic respiration detector responsive to respiratory effects appearing on a detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of respiration rate, the plethysmographic respiration detector comprising:
a preprocessor configured to identify a portion of a plethysmograph waveform which includes a physiologically acceptable series of plethysmograph waveform pulses;
one or more processors configured to use a plurality of different techniques to derive a plurality of different frequency spectrums using the portion of the plethysmograph waveform, each of the plurality of different frequency spectrums responsive to at least one respiratory effect on the portion of the plethysmograph waveform and including a plurality of local maximums, the one or more processors comprising:
a baseline processor configured to receive the portion of the plethysmograph waveform and output a baseline frequency spectrum responsive to a respiratory-induced baseline shift of the portion of the plethysmograph waveform,
an amplitude modulation (AM) processor configured to receive the portion of the plethysmograph waveform and output an AM frequency spectrum responsive to a respiratory-induced amplitude modulation of the portion of the plethysmograph waveform, and
a shape modulation (SM) processor configured to receive the portion of the plethysmograph waveform and output a SM frequency spectrum responsive to a respiratory-induced shape modulation of the portion of the plethysmograph waveform,
wherein a first frequency spectrum of the plurality of different frequency spectrums is one of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum, and a second frequency spectrum of the plurality of different frequency spectrums is different from the first frequency spectrum and is one of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum; and
a decision logic configured to determine a respiration rate based at least on a comparison of one or more local maximums of the first frequency spectrum and one or more local maximums of the second frequency spectrum, the decision logic comprising:
a peak detector configured to operate on each of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum so as to determine the local maximums of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum, and
a comparator configured to determine if the local maximums of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum occur at matching frequencies within a first tolerance,
wherein the decision logic is configured to generate a respiration rate output if the comparator finds at least one local maximum of each of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum occur at matching frequencies within the first tolerance.
13. The plethysmographic respiration detector according to claim 12 wherein the decision logic is configured to determine the respiration rate a plurality of times over portions of the plethysmograph waveform to generate a plurality of respiration rate outputs, and further comprising a smoother configured to operate on the plurality of the respiration rate outputs so as to derive a smoothed respiration rate output.
14. The plethysmographic respiration detector according to claim 12 wherein the decision logic is further configured to reject an additional respiration rate if it differs from the smoothed respiration rate output by more than a first amount.
15. The plethysmographic respiration detector according to claim 12 wherein the respiration rate comprises a frequency of one of the local maximums of the first frequency spectrum.
16. The plethysmographic respiration detector according to claim 12 wherein the baseline processor comprises:
a first signal conditioner configured to generate a first conditioned pleth from the portion of the plethysmograph waveform; and
a first frequency transform configured to receive the first conditioned pleth and generate the baseline frequency spectrum,
wherein the first frequency spectrum is the baseline frequency spectrum.
17. The plethysmographic respiration detector according to claim 12 wherein the AM processor comprises:
a second signal conditioner configured to generate a second conditioned pleth from the portion of the plethysmograph waveform;
a demodulator configured to demodulate the second conditioned pleth to generate a demodulated pleth; and
a second frequency transform configured to receive the demodulated pleth and generate the AM frequency spectrum,
wherein the first frequency spectrum is the AM frequency spectrum.
18. The plethysmographic respiration detector according to claim 12 wherein the SM processor comprises:
a third signal conditioner configured to generate a third conditioned pleth from the portion of the plethysmograph waveform;
a feature extractor configured to generate a modulated metric from the third conditioned pleth; and
a third frequency transform configured to generate the SM frequency spectrum based at least on the modulated metric,
wherein the first frequency spectrum is the SM frequency spectrum.
Patent Citations (541)
| Patent | Date | Inventor | Cited By |
|---|---|---|---|
| US3682161(A) | 1972-08-01 | Alibert | Applicant |
| US4127749(A) | 1978-11-01 | Atoji et al. | Applicant |
| US4326143(A) | 1982-04-01 | Guth et al. | Applicant |
| US4537200(A) | 1985-08-01 | Widrow | Applicant |
| US4884809(A) | 1989-12-01 | Rowan | Applicant |
| US4958638(A) | 1990-09-01 | Sharpe et al. | Applicant |
| US4960128(A) | 1990-10-01 | Gordon et al. | Applicant |
| US4964408(A) | 1990-10-01 | Hink et al. | Applicant |
| US5033032(A) | 1991-07-01 | Houghtaling | Applicant |
| US5041187(A) | 1991-08-01 | Hink et al. | Applicant |
| US5069213(A) | 1991-12-01 | Polczynski | Applicant |
| US5143078(A) | 1992-09-01 | Mather et al. | Applicant |
| US5163438(A) | 1992-11-01 | Gordon et al. | Applicant |
| US5319355(A) | 1994-06-01 | Russek | Applicant |
| US5337744(A) | 1994-08-01 | Branigan | Applicant |
| US5341805(A) | 1994-08-01 | Stavridi et al. | Applicant |
| USD353195(S) | 1994-12-01 | Savage et al. | Applicant |
| USD353196(S) | 1994-12-01 | Savage et al. | Applicant |
| US5377302(A) | 1994-12-01 | Tsiang | Applicant |
| US5377676(A) | 1995-01-01 | Vari et al. | Applicant |
| USD359546(S) | 1995-06-01 | Savage et al. | Applicant |
| US5431170(A) | 1995-07-01 | Mathews | Applicant |
| USD361840(S) | 1995-08-01 | Savage et al. | Applicant |
| USD362063(S) | 1995-09-01 | Savage et al. | Applicant |
| US5448996(A) | 1995-09-01 | Bellin et al. | Applicant |
| US5452717(A) | 1995-09-01 | Branigan et al. | Applicant |
| USD363120(S) | 1995-10-01 | Savage et al. | Applicant |
| US5456252(A) | 1995-10-01 | Vari et al. | Applicant |
| US5479934(A) | 1996-01-01 | Imran | Applicant |
| US5482036(A) | 1996-01-01 | Diab et al. | Applicant |
| US5490505(A) | 1996-02-01 | Diab et al. | Applicant |
| US5494043(A) | 1996-02-01 | O'Sullivan et al. | Applicant |
| US5533511(A) | 1996-07-01 | Kaspari et al. | Applicant |
| US5534851(A) | 1996-07-01 | Russek | Applicant |
| US5561275(A) | 1996-10-01 | Savage et al. | Applicant |
| US5562002(A) | 1996-10-01 | Lalin | Applicant |
| US5590649(A) | 1997-01-01 | Caro et al. | Applicant |
| US5602924(A) | 1997-02-01 | Durand et al. | Applicant |
| US5632272(A) | 1997-05-01 | Diab et al. | Applicant |
| US5638403(A) | 1997-06-01 | Birchler et al. | Applicant |
| US5638816(A) | 1997-06-01 | Kiani-Azarbayjany et al. | Applicant |
| US5638818(A) | 1997-06-01 | Diab et al. | Applicant |
| US5645440(A) | 1997-07-01 | Tobler et al. | Applicant |
| US5685299(A) | 1997-11-01 | Diab et al. | Applicant |
| US5724983(A) | 1998-03-01 | Selker et al. | Applicant |
| USD393830(S) | 1998-04-01 | Tobler et al. | Applicant |
| US5743262(A) | 1998-04-01 | Lepper, Jr. et al. | Applicant |
| US5758644(A) | 1998-06-01 | Diab et al. | Applicant |
| US5760910(A) | 1998-06-01 | Lepper, Jr. et al. | Applicant |
| US5769785(A) | 1998-06-01 | Diab et al. | Applicant |
| US5782757(A) | 1998-07-01 | Diab et al. | Applicant |
| US5785659(A) | 1998-07-01 | Caro et al. | Applicant |
| US5791347(A) | 1998-08-01 | Flaherty et al. | Applicant |
| US5810734(A) | 1998-09-01 | Caro et al. | Applicant |
| US5819007(A) | 1998-10-01 | Elghazzawi | Applicant |
| US5823950(A) | 1998-10-01 | Diab et al. | Applicant |
| US5830131(A) | 1998-11-01 | Caro et al. | Applicant |
| US5833618(A) | 1998-11-01 | Caro et al. | Applicant |
| US5860919(A) | 1999-01-01 | Kiani-Azarbayjany et al. | Applicant |
| US5865736(A) | 1999-02-01 | Baker, Jr. et al. | Applicant |
| US5890929(A) | 1999-04-01 | Mills et al. | Applicant |
| US5904654(A) | 1999-05-01 | Wohltmann et al. | Applicant |
| US5919134(A) | 1999-07-01 | Diab | Applicant |
| US5928156(A) | 1999-07-01 | Krumbiegel | Applicant |
| US5934925(A) | 1999-08-01 | Tobler et al. | Applicant |
| US5940182(A) | 1999-08-01 | Lepper, Jr. et al. | Applicant |
| US5995855(A) | 1999-11-01 | Kiani et al. | Applicant |
| US5997343(A) | 1999-12-01 | Mills et al. | Applicant |
| US6002952(A) | 1999-12-01 | Diab et al. | Applicant |
| US6011986(A) | 2000-01-01 | Diab et al. | Applicant |
| US6027452(A) | 2000-02-01 | Flaherty et al. | Applicant |
| US6029665(A) | 2000-02-01 | Berthon-Jones | Applicant |
| US6036642(A) | 2000-03-01 | Diab et al. | Applicant |
| US6045509(A) | 2000-04-01 | Caro et al. | Applicant |
| US6064910(A) | 2000-05-01 | Andersson et al. | Applicant |
| US6067462(A) | 2000-05-01 | Diab et al. | Applicant |
| US6081735(A) | 2000-06-01 | Diab et al. | Applicant |
| US6083172(A) | 2000-07-01 | Baker et al. | Applicant |
| US6088607(A) | 2000-07-01 | Diab et al. | Applicant |
| US6110522(A) | 2000-08-01 | Lepper, Jr. et al. | Applicant |
| US6112171(A) | 2000-08-01 | Sugiyama et al. | Applicant |
| US6124597(A) | 2000-09-01 | Shehada | Applicant |
| US6128521(A) | 2000-10-01 | Marro et al. | Applicant |
| US6129675(A) | 2000-10-01 | Jay | Applicant |
| US6138675(A) | 2000-10-01 | Berthon-Jones | Applicant |
| US6144868(A) | 2000-11-01 | Parker | Applicant |
| US6151516(A) | 2000-11-01 | Kiani-Azarbayjany et al. | Applicant |
| US6152754(A) | 2000-11-01 | Gerhardt et al. | Applicant |
| US6157850(A) | 2000-12-01 | Diab et al. | Applicant |
| US6165005(A) | 2000-12-01 | Mills et al. | Applicant |
| US6168568(B1) | 2001-01-01 | Gavriely | Applicant |
| US6184521(B1) | 2001-02-01 | Coffin, IV et al. | Applicant |
| US6206830(B1) | 2001-03-01 | Diab et al. | Applicant |
| US6229856(B1) | 2001-05-01 | Diab et al. | Applicant |
| US6232609(B1) | 2001-05-01 | Snyder et al. | Applicant |
| US6236872(B1) | 2001-05-01 | Diab et al. | Applicant |
| US6241683(B1) | 2001-06-01 | Macklem et al. | Applicant |
| US6248083(B1) | 2001-06-01 | Smith et al. | Applicant |
| US6253097(B1) | 2001-06-01 | Aronow et al. | Applicant |
| US6254551(B1) | 2001-07-01 | Varis | Applicant |
| US6256523(B1) | 2001-07-01 | Diab et al. | Applicant |
| US6263222(B1) | 2001-07-01 | Diab et al. | Applicant |
| US6278522(B1) | 2001-08-01 | Lepper, Jr. et al. | Applicant |
| US6280213(B1) | 2001-08-01 | Tobler et al. | Applicant |
| US6285896(B1) | 2001-09-01 | Tobler et al. | Applicant |
| US6301493(B1) | 2001-10-01 | Marro et al. | Applicant |
| US6317627(B1) | 2001-11-01 | Ennen et al. | Applicant |
| US6321100(B1) | 2001-11-01 | Parker | Applicant |
| US6325761(B1) | 2001-12-01 | Jay | Applicant |
| US6334065(B1) | 2001-12-01 | Al-Ali et al. | Applicant |
| US6343224(B1) | 2002-01-01 | Parker | Applicant |
| US6349228(B1) | 2002-02-01 | Kiani et al. | Applicant |
| US6360114(B1) | 2002-03-01 | Diab et al. | Applicant |
| US6368283(B1) | 2002-04-01 | Xu et al. | Applicant |
| US6371921(B1) | 2002-04-01 | Caro et al. | Applicant |
| US6377829(B1) | 2002-04-01 | Al-Ali | Applicant |
| US6388240(B2) | 2002-05-01 | Schulz et al. | Applicant |
| US6397091(B2) | 2002-05-01 | Diab et al. | Applicant |
| US6430437(B1) | 2002-08-01 | Marro | Applicant |
| US6430525(B1) | 2002-08-01 | Weber et al. | Applicant |
| US6443907(B1) | 2002-09-01 | Mansy et al. | Applicant |
| US6463311(B1) | 2002-10-01 | Diab | Applicant |
| US6470199(B1) | 2002-10-01 | Kopotic et al. | Applicant |
| US6486588(B2) | 2002-11-01 | Doron et al. | Applicant |
| US6491647(B1) | 2002-12-01 | Bridger et al. | Applicant |
| US6501975(B2) | 2002-12-01 | Diab et al. | Applicant |
| US6505059(B1) | 2003-01-01 | Kollias et al. | Applicant |
| US6515273(B2) | 2003-02-01 | Al-Ali | Applicant |
| US6517497(B2) | 2003-02-01 | Rymut et al. | Applicant |
| US6519487(B1) | 2003-02-01 | Parker | Applicant |
| US6525386(B1) | 2003-02-01 | Mills et al. | Applicant |
| US6526300(B1) | 2003-02-01 | Kiani et al. | Applicant |
| US6541756(B2) | 2003-04-01 | Schulz et al. | Applicant |
| US6542764(B1) | 2003-04-01 | Al-Ali et al. | Applicant |
| US6580086(B1) | 2003-06-01 | Schulz et al. | Applicant |
| US6584336(B1) | 2003-06-01 | Ali et al. | Applicant |
| US6595316(B2) | 2003-07-01 | Cybulski et al. | Applicant |
| US6597932(B2) | 2003-07-01 | Tian et al. | Applicant |
| US6597933(B2) | 2003-07-01 | Kiani et al. | Applicant |
| US6606511(B1) | 2003-08-01 | Ali et al. | Applicant |
| US6632181(B2) | 2003-10-01 | Flaherty et al. | Applicant |
| US6639668(B1) | 2003-10-01 | Trepagnier | Applicant |
| US6640116(B2) | 2003-10-01 | Diab | Applicant |
| US6643530(B2) | 2003-11-01 | Diab et al. | Applicant |
| US6647280(B2) | 2003-11-01 | Bahr et al. | Applicant |
| US6650917(B2) | 2003-11-01 | Diab et al. | Applicant |
| US6654624(B2) | 2003-11-01 | Diab et al. | Applicant |
| US6658276(B2) | 2003-12-01 | Kianl et al. | Applicant |
| US6661161(B1) | 2003-12-01 | Lanzo et al. | Applicant |
| US6671531(B2) | 2003-12-01 | Al-Ali et al. | Applicant |
| US6678543(B2) | 2004-01-01 | Diab et al. | Applicant |
| US6684090(B2) | 2004-01-01 | Ali et al. | Applicant |
| US6684091(B2) | 2004-01-01 | Parker | Applicant |
| US6697656(B1) | 2004-02-01 | Al-Ali | Applicant |
| US6697657(B1) | 2004-02-01 | Shehada et al. | Applicant |
| US6697658(B2) | 2004-02-01 | Al-Ali | Applicant |
| USRE38476(E) | 2004-03-01 | Diab et al. | Applicant |
| US6699194(B1) | 2004-03-01 | Diab et al. | Applicant |
| US6714804(B2) | 2004-03-01 | Al-Ali et al. | Applicant |
| USRE38492(E) | 2004-04-01 | Diab et al. | Applicant |
| US6721582(B2) | 2004-04-01 | Trepagnier et al. | Applicant |
| US6721585(B1) | 2004-04-01 | Parker | Applicant |
| US6725075(B2) | 2004-04-01 | Al-Ali | Applicant |
| US6728560(B2) | 2004-04-01 | Kollias et al. | Applicant |
| US6735459(B2) | 2004-05-01 | Parker | Applicant |
| US6745060(B2) | 2004-06-01 | Diab et al. | Applicant |
| US6754516(B2) | 2004-06-01 | Mannheimer | Applicant |
| US6760607(B2) | 2004-07-01 | Al-Ali | Applicant |
| US6766038(B1) | 2004-07-01 | Sakuma et al. | Applicant |
| US6770028(B1) | 2004-08-01 | Ali et al. | Applicant |
| US6771994(B2) | 2004-08-01 | Kiani et al. | Applicant |
| US6792300(B1) | 2004-09-01 | Diab et al. | Applicant |
| US6813511(B2) | 2004-11-01 | Diab et al. | Applicant |
| US6816741(B2) | 2004-11-01 | Diab | Applicant |
| US6822564(B2) | 2004-11-01 | Al-Ali | Applicant |
| US6826419(B2) | 2004-11-01 | Diab et al. | Applicant |
| US6830711(B2) | 2004-12-01 | Mills et al. | Applicant |
| US6839581(B1) | 2005-01-01 | El-Solh et al. | Applicant |
| US6850787(B2) | 2005-02-01 | Weber et al. | Applicant |
| US6850788(B2) | 2005-02-01 | Al-Ali | Applicant |
| US6852083(B2) | 2005-02-01 | Caro et al. | Applicant |
| US6861639(B2) | 2005-03-01 | Al-Ali | Applicant |
| US6898452(B2) | 2005-05-01 | Al-Ali et al. | Applicant |
| US6920345(B2) | 2005-07-01 | Al-Ali et al. | Applicant |
| US6931268(B1) | 2005-08-01 | Kiani-Azarbayjany et al. | Applicant |
| US6934570(B2) | 2005-08-01 | Kiani et al. | Applicant |
| US6939305(B2) | 2005-09-01 | Flaherty et al. | Applicant |
| US6943348(B1) | 2005-09-01 | Coffin, IV | Applicant |
| US6950687(B2) | 2005-09-01 | Al-Ali | Applicant |
| US6961598(B2) | 2005-11-01 | Diab | Applicant |
| US6970792(B1) | 2005-11-01 | Diab | Applicant |
| US6979812(B2) | 2005-12-01 | Al-Ali | Applicant |
| US6985764(B2) | 2006-01-01 | Mason et al. | Applicant |
| US6993371(B2) | 2006-01-01 | Kiani et al. | Applicant |
| US6996427(B2) | 2006-02-01 | Ali et al. | Applicant |
| US6999904(B2) | 2006-02-01 | Weber et al. | Applicant |
| US7003338(B2) | 2006-02-01 | Weber et al. | Applicant |
| US7003339(B2) | 2006-02-01 | Diab et al. | Applicant |
| US7015451(B2) | 2006-03-01 | Dalke et al. | Applicant |
| US7024233(B2) | 2006-04-01 | Ali et al. | Applicant |
| US7027849(B2) | 2006-04-01 | Al-Ali | Applicant |
| US7030749(B2) | 2006-04-01 | Al-Ali | Applicant |
| US7039449(B2) | 2006-05-01 | Al-Ali | Applicant |
| US7041060(B2) | 2006-05-01 | Flaherty et al. | Applicant |
| US7044918(B2) | 2006-05-01 | Diab | Applicant |
| US7067893(B2) | 2006-06-01 | Mills et al. | Applicant |
| US7096052(B2) | 2006-08-01 | Mason et al. | Applicant |
| US7096054(B2) | 2006-08-01 | Abdul-Hafiz et al. | Applicant |
| US7096060(B2) | 2006-08-01 | Arand et al. | Applicant |
| US7132641(B2) | 2006-11-01 | Schulz et al. | Applicant |
| US7142901(B2) | 2006-11-01 | Kiani et al. | Applicant |
| US7149561(B2) | 2006-12-01 | Diab | Applicant |
| US7186966(B2) | 2007-03-01 | Al-Ali | Applicant |
| US7190261(B2) | 2007-03-01 | Al-Ali | Applicant |
| US7194306(B1) | 2007-03-01 | Turcott | Applicant |
| US7215984(B2) | 2007-05-01 | Diab | Applicant |
| US7215986(B2) | 2007-05-01 | Diab | Applicant |
| US7221971(B2) | 2007-05-01 | Diab | Applicant |
| US7225006(B2) | 2007-05-01 | Al-Ali et al. | Applicant |
| US7225007(B2) | 2007-05-01 | Al-Ali | Applicant |
| USRE39672(E) | 2007-06-01 | Shehada et al. | Applicant |
| US7239905(B2) | 2007-07-01 | Kiani-Azarbayjany et al. | Applicant |
| US7245953(B1) | 2007-07-01 | Parker | Applicant |
| US7254429(B2) | 2007-08-01 | Schurman et al. | Applicant |
| US7254431(B2) | 2007-08-01 | Al-Ali | Applicant |
| US7254433(B2) | 2007-08-01 | Diab et al. | Applicant |
| US7254434(B2) | 2007-08-01 | Schulz et al. | Applicant |
| US7272425(B2) | 2007-09-01 | Al-Ali | Applicant |
| US7274955(B2) | 2007-09-01 | Kiani et al. | Applicant |
| USD554263(S) | 2007-10-01 | Al-Ali | Applicant |
| US7280858(B2) | 2007-10-01 | Al-Ali et al. | Applicant |
| US7289835(B2) | 2007-10-01 | Mansfield et al. | Applicant |
| US7292883(B2) | 2007-11-01 | De Felice et al. | Applicant |
| US7295866(B2) | 2007-11-01 | Al-Ali | Applicant |
| US7328053(B1) | 2008-02-01 | Diab et al. | Applicant |
| US7332784(B2) | 2008-02-01 | Mills et al. | Applicant |
| US7340287(B2) | 2008-03-01 | Mason et al. | Applicant |
| US7341559(B2) | 2008-03-01 | Schulz et al. | Applicant |
| US7343186(B2) | 2008-03-01 | Lamego et al. | Applicant |
| USD566282(S) | 2008-04-01 | Al-Ali et al. | Applicant |
| US7355512(B1) | 2008-04-01 | Al-Ali | Applicant |
| US7356365(B2) | 2008-04-01 | Schurman | Applicant |
| US7371981(B2) | 2008-05-01 | Abdul-Hafiz | Applicant |
| US7373193(B2) | 2008-05-01 | Al-Ali et al. | Applicant |
| US7373194(B2) | 2008-05-01 | Weber et al. | Applicant |
| US7376453(B1) | 2008-05-01 | Diab et al. | Applicant |
| US7377794(B2) | 2008-05-01 | Al-Ali et al. | Applicant |
| US7377899(B2) | 2008-05-01 | Weber et al. | Applicant |
| US7383070(B2) | 2008-06-01 | Diab et al. | Applicant |
| US7398115(B2) | 2008-07-01 | Lynn | Applicant |
| US7415297(B2) | 2008-08-01 | Al-Ali et al. | Applicant |
| US7428432(B2) | 2008-09-01 | Ali et al. | Applicant |
| US7438683(B2) | 2008-10-01 | Al-Ali et al. | Applicant |
| US7440787(B2) | 2008-10-01 | Diab | Applicant |
| US7454240(B2) | 2008-11-01 | Diab et al. | Applicant |
| US7467002(B2) | 2008-12-01 | Weber et al. | Applicant |
| US7469157(B2) | 2008-12-01 | Diab et al. | Applicant |
| US7471969(B2) | 2008-12-01 | Diab et al. | Applicant |
| US7471971(B2) | 2008-12-01 | Diab et al. | Applicant |
| US7483729(B2) | 2009-01-01 | Al-Ali et al. | Applicant |
| US7483730(B2) | 2009-01-01 | Diab et al. | Applicant |
| US7489958(B2) | 2009-02-01 | Diab et al. | Applicant |
| US7496391(B2) | 2009-02-01 | Diab et al. | Applicant |
| US7496393(B2) | 2009-02-01 | Diab et al. | Applicant |
| USD587657(S) | 2009-03-01 | Al-Ali et al. | Applicant |
| US7499741(B2) | 2009-03-01 | Diab et al. | Applicant |
| US7499835(B2) | 2009-03-01 | Weber et al. | Applicant |
| US7500950(B2) | 2009-03-01 | Al-Ali et al. | Applicant |
| US7509154(B2) | 2009-03-01 | Diab et al. | Applicant |
| US7509494(B2) | 2009-03-01 | Al-Ali | Applicant |
| US7510849(B2) | 2009-03-01 | Schurman et al. | Applicant |
| US7526328(B2) | 2009-04-01 | Diab et al. | Applicant |
| US7530942(B1) | 2009-05-01 | Diab | Applicant |
| US7530949(B2) | 2009-05-01 | Al Ali et al. | Applicant |
| US7530955(B2) | 2009-05-01 | Diab et al. | Applicant |
| US7539533(B2) | 2009-05-01 | Tran | Applicant |
| US7563110(B2) | 2009-07-01 | Al-Ali et al. | Applicant |
| US7596398(B2) | 2009-09-01 | Al-Ali et al. | Applicant |
| US7618375(B2) | 2009-11-01 | Flaherty | Applicant |
| USD606659(S) | 2009-12-01 | Kiani et al. | Applicant |
| US7647083(B2) | 2010-01-01 | Al-Ali et al. | Applicant |
| USD609193(S) | 2010-02-01 | Al-Ali et al. | Applicant |
| USD614305(S) | 2010-04-01 | Al-Ali et al. | Applicant |
| US7690378(B1) | 2010-04-01 | Turcott | Applicant |
| USRE41317(E) | 2010-05-01 | Parker | Applicant |
| US7729733(B2) | 2010-06-01 | Al-Ali et al. | Applicant |
| US7734320(B2) | 2010-06-01 | Al-Ali | Applicant |
| US7761127(B2) | 2010-07-01 | Al-Ali et al. | Applicant |
| US7761128(B2) | 2010-07-01 | Al-Ali et al. | Applicant |
| US7764982(B2) | 2010-07-01 | Dalke et al. | Applicant |
| USD621516(S) | 2010-08-01 | Kiani et al. | Applicant |
| US7791155(B2) | 2010-09-01 | Diab | Applicant |
| US7801581(B2) | 2010-09-01 | Diab | Applicant |
| US7822452(B2) | 2010-10-01 | Schurman et al. | Applicant |
| USRE41912(E) | 2010-11-01 | Parker | Applicant |
| US7844313(B2) | 2010-11-01 | Kiani et al. | Applicant |
| US7844314(B2) | 2010-11-01 | Al-Ali | Applicant |
| US7844315(B2) | 2010-11-01 | Al-Ali | Applicant |
| US7865222(B2) | 2011-01-01 | Weber et al. | Applicant |
| US7873497(B2) | 2011-01-01 | Weber et al. | Applicant |
| US7880606(B2) | 2011-02-01 | Al-Ali | Applicant |
| US7880626(B2) | 2011-02-01 | Al-Ali et al. | Applicant |
| US7891355(B2) | 2011-02-01 | Al-Ali et al. | Applicant |
| US7894868(B2) | 2011-02-01 | Al-Ali et al. | Applicant |
| US7899507(B2) | 2011-03-01 | Al-Ali et al. | Applicant |
| US7899518(B2) | 2011-03-01 | Trepagnier et al. | Applicant |
| US7904132(B2) | 2011-03-01 | Weber et al. | Applicant |
| US7909772(B2) | 2011-03-01 | Popov et al. | Applicant |
| US7910875(B2) | 2011-03-01 | Al-Ali | Applicant |
| US7919713(B2) | 2011-04-01 | Al-Ali et al. | Applicant |
| US7937128(B2) | 2011-05-01 | Al-Ali | Applicant |
| US7937129(B2) | 2011-05-01 | Mason et al. | Applicant |
| US7937130(B2) | 2011-05-01 | Diab et al. | Applicant |
| US7941199(B2) | 2011-05-01 | Kiani | Applicant |
| US7951086(B2) | 2011-05-01 | Flaherty et al. | Applicant |
| US7957780(B2) | 2011-06-01 | Lamego et al. | Applicant |
| US7962188(B2) | 2011-06-01 | Kiani et al. | Applicant |
| US7962190(B1) | 2011-06-01 | Diab et al. | Applicant |
| US7976472(B2) | 2011-07-01 | Kiani | Applicant |
| US7988637(B2) | 2011-08-01 | Diab | Applicant |
| US7990382(B2) | 2011-08-01 | Kiani | Applicant |
| US7991446(B2) | 2011-08-01 | Al-Ali et al. | Applicant |
| US8000761(B2) | 2011-08-01 | Al-Ali | Applicant |
| US8008088(B2) | 2011-08-01 | Bellott et al. | Applicant |
| USRE42753(E) | 2011-09-01 | Kiani-Azarbayjany et al. | Applicant |
| US8019400(B2) | 2011-09-01 | Diab et al. | Applicant |
| US8028701(B2) | 2011-10-01 | Al-Ali et al. | Applicant |
| US8029765(B2) | 2011-10-01 | Bellott et al. | Applicant |
| US8036728(B2) | 2011-10-01 | Diab et al. | Applicant |
| US8046040(B2) | 2011-10-01 | Ali et al. | Applicant |
| US8046041(B2) | 2011-10-01 | Diab et al. | Applicant |
| US8046042(B2) | 2011-10-01 | Diab et al. | Applicant |
| US8048040(B2) | 2011-11-01 | Kiani | Applicant |
| US8050728(B2) | 2011-11-01 | Al-Ali et al. | Applicant |
| USRE43169(E) | 2012-02-01 | Parker | Applicant |
| US8118620(B2) | 2012-02-01 | Al-Ali et al. | Applicant |
| US8126528(B2) | 2012-02-01 | Diab et al. | Applicant |
| US8128572(B2) | 2012-03-01 | Diab et al. | Applicant |
| US8130105(B2) | 2012-03-01 | Al-Ali et al. | Applicant |
| US8145287(B2) | 2012-03-01 | Diab et al. | Applicant |
| US8150487(B2) | 2012-04-01 | Diab et al. | Applicant |
| US8175672(B2) | 2012-05-01 | Parker | Applicant |
| US8180420(B2) | 2012-05-01 | Diab et al. | Applicant |
| US8182443(B1) | 2012-05-01 | Kiani | Applicant |
| US8185180(B2) | 2012-05-01 | Diab et al. | Applicant |
| US8190223(B2) | 2012-05-01 | Al-Ali et al. | Applicant |
| US8190227(B2) | 2012-05-01 | Diab et al. | Applicant |
| US8203438(B2) | 2012-06-01 | Kiani et al. | Applicant |
| US8224411(B2) | 2012-07-01 | Al-Ali et al. | Applicant |
| US8228181(B2) | 2012-07-01 | Al-Ali | Applicant |
| US8229533(B2) | 2012-07-01 | Diab et al. | Applicant |
| US8255026(B1) | 2012-08-01 | Al-Ali | Applicant |
| US8255028(B2) | 2012-08-01 | Al-Ali et al. | Applicant |
| US8260577(B2) | 2012-09-01 | Weber et al. | Applicant |
| US8274360(B2) | 2012-09-01 | Sampath et al. | Applicant |
| US8301217(B2) | 2012-10-01 | Al-Ali et al. | Applicant |
| US8306596(B2) | 2012-11-01 | Schurman et al. | Applicant |
| US8310336(B2) | 2012-11-01 | Muhsin et al. | Applicant |
| US8315683(B2) | 2012-11-01 | Al-Ali et al. | Applicant |
| USRE43860(E) | 2012-12-01 | Parker | Applicant |
| US8337403(B2) | 2012-12-01 | Al-Ali et al. | Applicant |
| US8346330(B2) | 2013-01-01 | Lamego | Applicant |
| US8353842(B2) | 2013-01-01 | Al-Ali et al. | Applicant |
| US8355766(B2) | 2013-01-01 | MacNeish, III et al. | Applicant |
| US8359080(B2) | 2013-01-01 | Diab et al. | Applicant |
| US8364223(B2) | 2013-01-01 | Al-Ali et al. | Applicant |
| US8364226(B2) | 2013-01-01 | Diab et al. | Applicant |
| US8374665(B2) | 2013-02-01 | Lamego | Applicant |
| US8385995(B2) | 2013-02-01 | Al-Ali et al. | Applicant |
| US8385996(B2) | 2013-02-01 | Smith et al. | Applicant |
| US8388353(B2) | 2013-03-01 | Kiani et al. | Applicant |
| US8399822(B2) | 2013-03-01 | Al-Ali | Applicant |
| US8401602(B2) | 2013-03-01 | Kiani | Applicant |
| US8405608(B2) | 2013-03-01 | Al-Ali et al. | Applicant |
| US8414499(B2) | 2013-04-01 | Al-Ali et al. | Applicant |
| US8418524(B2) | 2013-04-01 | Al-Ali | Applicant |
| US8423106(B2) | 2013-04-01 | Lamego et al. | Applicant |
| US8428967(B2) | 2013-04-01 | Olsen et al. | Applicant |
| US8430817(B1) | 2013-04-01 | Al-Ali et al. | Applicant |
| US8437825(B2) | 2013-05-01 | Dalvi et al. | Applicant |
| US8455290(B2) | 2013-06-01 | Siskavich | Applicant |
| US8457703(B2) | 2013-06-01 | Al-Ali | Applicant |
| US8457707(B2) | 2013-06-01 | Kiani | Applicant |
| US8463349(B2) | 2013-06-01 | Diab et al. | Applicant |
| US8466286(B2) | 2013-06-01 | Bellott et al. | Applicant |
| US8471713(B2) | 2013-06-01 | Poeze et al. | Applicant |
| US8473020(B2) | 2013-06-01 | Kiani et al. | Applicant |
| US8483787(B2) | 2013-07-01 | Al-Ali et al. | Applicant |
| US8489364(B2) | 2013-07-01 | Weber et al. | Applicant |
| US8498684(B2) | 2013-07-01 | Weber et al. | Applicant |
| US8504128(B2) | 2013-08-01 | Blank et al. | Applicant |
| US8509867(B2) | 2013-08-01 | Workman et al. | Applicant |
| US8515509(B2) | 2013-08-01 | Bruinsma et al. | Applicant |
| US8529301(B2) | 2013-09-01 | Al-Ali et al. | Applicant |
| US8532727(B2) | 2013-09-01 | Ali et al. | Applicant |
| US8532728(B2) | 2013-09-01 | Diab et al. | Applicant |
| USD692145(S) | 2013-10-01 | Al-Ali et al. | Applicant |
| US8547209(B2) | 2013-10-01 | Kiani et al. | Applicant |
| US8548548(B2) | 2013-10-01 | Al-Ali | Applicant |
| US8548549(B2) | 2013-10-01 | Schurman et al. | Applicant |
| US8548550(B2) | 2013-10-01 | Al-Ali et al. | Applicant |
| US8560032(B2) | 2013-10-01 | Al-Ali et al. | Applicant |
| US8560034(B1) | 2013-10-01 | Diab et al. | Applicant |
| US8570167(B2) | 2013-10-01 | Al-Ali | Applicant |
| US8570503(B2) | 2013-10-01 | Vo et al. | Applicant |
| US8571617(B2) | 2013-10-01 | Reichgott et al. | Applicant |
| US8571618(B1) | 2013-10-01 | Lamego et al. | Applicant |
| US8571619(B2) | 2013-10-01 | Al-Ali et al. | Applicant |
| US8577431(B2) | 2013-11-01 | Lamego et al. | Applicant |
| US8584345(B2) | 2013-11-01 | Al-Ali et al. | Applicant |
| US8588880(B2) | 2013-11-01 | Abdul-Hafiz et al. | Applicant |
| US8600467(B2) | 2013-12-01 | Al-Ali et al. | Applicant |
| US8606342(B2) | 2013-12-01 | Diab | Applicant |
| US8626255(B2) | 2014-01-01 | Al-Ali et al. | Applicant |
| US8630691(B2) | 2014-01-01 | Lamego et al. | Applicant |
| US8634889(B2) | 2014-01-01 | Al-Ali et al. | Applicant |
| US8641631(B2) | 2014-02-01 | Sierra et al. | Applicant |
| US8652060(B2) | 2014-02-01 | Al-Ali | Applicant |
| US8663107(B2) | 2014-03-01 | Kiani | Applicant |
| US8666468(B1) | 2014-03-01 | Al-Ali | Applicant |
| US8667967(B2) | 2014-03-01 | Al-Ali et al. | Applicant |
| US8670811(B2) | 2014-03-01 | O'Reilly | Applicant |
| US8670814(B2) | 2014-03-01 | Diab et al. | Applicant |
| US8676286(B2) | 2014-03-01 | Weber et al. | Applicant |
| US8682407(B2) | 2014-03-01 | Al-Ali | Applicant |
| USRE44823(E) | 2014-04-01 | Parker | Applicant |
| USRE44875(E) | 2014-04-01 | Kiani et al. | Applicant |
| US8700112(B2) | 2014-04-01 | Kiani | Applicant |
| US8706179(B2) | 2014-04-01 | Parker | Applicant |
| US8712494(B1) | 2014-04-01 | MacNeish, III et al. | Applicant |
| US8718735(B2) | 2014-05-01 | Lamego et al. | Applicant |
| US8718737(B2) | 2014-05-01 | Diab et al. | Applicant |
| US8718738(B2) | 2014-05-01 | Blank et al. | Applicant |
| US8720249(B2) | 2014-05-01 | Al-Ali | Applicant |
| US8721541(B2) | 2014-05-01 | Al-Ali et al. | Applicant |
| US8721542(B2) | 2014-05-01 | Al-Ali et al. | Applicant |
| US8723677(B1) | 2014-05-01 | Kiani | Applicant |
| US8740792(B1) | 2014-06-01 | Kiani et al. | Applicant |
| US8754776(B2) | 2014-06-01 | Poeze et al. | Applicant |
| US8755856(B2) | 2014-06-01 | Diab et al. | Applicant |
| US8755872(B1) | 2014-06-01 | Marinow | Applicant |
| US8761850(B2) | 2014-06-01 | Lamego | Applicant |
| US8764671(B2) | 2014-07-01 | Kiani | Applicant |
| US8768423(B2) | 2014-07-01 | Shakespeare et al. | Applicant |
| US8771204(B2) | 2014-07-01 | Telfort et al. | Applicant |
| US2001/0002206(A1) | 2001-05-01 | Diab et al. | Examiner |
| US2002/0193670(A1) | 2002-12-01 | Garfield et al. | Applicant |
| US2003/0015368(A1) | 2003-01-01 | Cybulski et al. | Applicant |
| US2003/0076494(A1) | 2003-04-01 | Bonin et al. | Applicant |
| US2003/0158466(A1) | 2003-08-01 | Lynn et al. | Applicant |
| US2003/0163054(A1) | 2003-08-01 | Dekker | Examiner |
| US2004/0010202(A1) | 2004-01-01 | Nakatani | Applicant |
| US2004/0059203(A1) | 2004-03-01 | Guerrero | Applicant |
| US2004/0133087(A1) | 2004-07-01 | Ali et al. | Applicant |
| US2004/0158162(A1) | 2004-08-01 | Narimatsu | Applicant |
| US2005/0027205(A1) | 2005-02-01 | Tarassenko et al. | Examiner |
| US2005/0048456(A1) | 2005-03-01 | Chefd'hotel et al. | Examiner |
| US2005/0070774(A1) | 2005-03-01 | Addison et al. | Applicant |
| US2006/0047215(A1) | 2006-03-01 | Newman et al. | Applicant |
| US2006/0149144(A1) | 2006-07-01 | Lynn et al. | Applicant |
| US2006/0155206(A1) | 2006-07-01 | Lynn | Applicant |
| US2006/0155207(A1) | 2006-07-01 | Lynn et al. | Applicant |
| US2006/0161071(A1) | 2006-07-01 | Lynn et al. | Applicant |
| US2006/0189880(A1) | 2006-08-01 | Lynn et al. | Applicant |
| US2006/0195041(A1) | 2006-08-01 | Lynn et al. | Applicant |
| US2006/0235324(A1) | 2006-10-01 | Lynn | Applicant |
| US2006/0238333(A1) | 2006-10-01 | Welch et al. | Applicant |
| US2006/0241510(A1) | 2006-10-01 | Halperin et al. | Applicant |
| US2006/0258921(A1) | 2006-11-01 | Addison et al. | Examiner |
| US2007/0093721(A1) | 2007-04-01 | Lynn et al. | Applicant |
| US2007/0129643(A1) | 2007-06-01 | Kwok et al. | Applicant |
| US2007/0129647(A1) | 2007-06-01 | Lynn | Applicant |
| US2007/0135725(A1) | 2007-06-01 | Hatlestad | Applicant |
| US2007/0149860(A1) | 2007-06-01 | Lynn et al. | Applicant |
| US2007/0185397(A1) | 2007-08-01 | Govari et al. | Applicant |
| US2007/0239057(A1) | 2007-10-01 | Pu et al. | Applicant |
| US2007/0282212(A1) | 2007-12-01 | Sierra et al. | Applicant |
| US2008/0039735(A1) | 2008-02-01 | Hickerson | Applicant |
| US2008/0071185(A1) | 2008-03-01 | Beck et al. | Applicant |
| US2008/0076972(A1) | 2008-03-01 | Dorogusker et al. | Applicant |
| US2008/0119716(A1) | 2008-05-01 | Boric-Lubecke et al. | Applicant |
| US2008/0161878(A1) | 2008-07-01 | Tehrani et al. | Applicant |
| US2008/0218153(A1) | 2008-09-01 | Patel et al. | Applicant |
| US2008/0275349(A1) | 2008-11-01 | Halperin et al. | Applicant |
| US2008/0304580(A1) | 2008-12-01 | Ichiyama | Examiner |
| US2009/0018429(A1) | 2009-01-01 | Saliga et al. | Applicant |
| US2009/0018453(A1) | 2009-01-01 | Banet et al. | Applicant |
| US2009/0093687(A1) | 2009-04-01 | Telfort et al. | Applicant |
| US2009/0112096(A1) | 2009-04-01 | Tamura | Applicant |
| US2009/0187065(A1) | 2009-07-01 | Basinger | Applicant |
| US2009/0299157(A1) | 2009-12-01 | Telfort et al. | Applicant |
| US2010/0004552(A1) | 2010-01-01 | Zhang et al. | Applicant |
| US2010/0016682(A1) | 2010-01-01 | Schluess et al. | Examiner |
| US2010/0274099(A1) | 2010-10-01 | Telfort et al. | Applicant |
| US2010/0298661(A1) | 2010-11-01 | McCombie et al. | Applicant |
| US2010/0298730(A1) | 2010-11-01 | Tarassenko et al. | Examiner |
| US2010/0324377(A1) | 2010-12-01 | Woehrle | Applicant |
| US2011/0009710(A1) | 2011-01-01 | Kroeger et al. | Applicant |
| US2011/0118573(A1) | 2011-05-01 | McKenna | Applicant |
| US2011/0125060(A1) | 2011-05-01 | Telfort et al. | Applicant |
| US2011/0172551(A1) | 2011-07-01 | Al-Ali et al. | Applicant |
| US2011/0172561(A1) | 2011-07-01 | Kiani et al. | Applicant |
| US2011/0196211(A1) | 2011-08-01 | Al-Ali et al. | Applicant |
| US2011/0209915(A1) | 2011-09-01 | Telfort et al. | Applicant |
| US2011/0213271(A1) | 2011-09-01 | Telfort et al. | Applicant |
| US2011/0213272(A1) | 2011-09-01 | Telfort et al. | Applicant |
| US2011/0213273(A1) | 2011-09-01 | Telfort et al. | Applicant |
| US2011/0213274(A1) | 2011-09-01 | Telfort et al. | Applicant |
| US2012/0016255(A1) | 2012-01-01 | Masuo | Applicant |
| US2012/0253140(A1) | 2012-10-01 | Addison et al. | Applicant |
| US2014/0180154(A1) | 2014-06-01 | Sierra et al. | Applicant |
| CA2262236 | 2008-04-01 | Applicant | |
| EP716628 | 1998-12-01 | Applicant | |
| EP659058 | 1999-01-01 | Applicant | |
| EP1207536 | 2002-05-01 | Applicant | |
| GB2358546 | 1999-11-01 | Applicant | |
| JP62-14898 | 1987-01-01 | Applicant | |
| JP1-309872 | 1998-06-01 | Applicant | |
| JP10-155755 | 1998-06-01 | Applicant | |
| JP2001-50713 | 1999-05-01 | Applicant | |
| JP2003-329719 | 2003-11-01 | Applicant | |
| WO94/05207 | 1994-03-01 | Applicant | |
| WO94/13207 | 1994-06-01 | Applicant | |
| WO95/29632 | 1995-11-01 | Applicant | |
| WO99/53277 | 1999-10-01 | Applicant | |
| WO/10462 | 2000-03-01 | Applicant | |
| WO1/34033 | 2001-05-01 | Applicant | |
| WO1/78059 | 2001-10-01 | Applicant | |
| WO1/97691 | 2001-12-01 | Applicant | |
| WO2/03042 | 2002-01-01 | Applicant | |
| WO3/058646 | 2003-07-01 | Applicant | |
| WO3/087737 | 2003-10-01 | Applicant | |
| WO2004/000111 | 2003-12-01 | Applicant | |
| WO2004/004411 | 2004-01-01 | Applicant | |
| WO2005/096931 | 2005-10-01 | Applicant | |
| WO2005/099562 | 2005-10-01 | Applicant | |
| WO2008/017246 | 2008-02-01 | Applicant | |
| WO2008/080469 | 2008-07-01 | Applicant | |
| WO2008/148172 | 2008-12-01 | Applicant | |
| WO2009/093159 | 2009-07-01 | Applicant | |
| WO2009/137524 | 2009-11-01 | Applicant |
Non-Patent Literature (17)
- Analog Devices, 12-Bit Serial Input Multiplying D/A Converter, Product Data Sheet, 2000.Applicant
- Chambrin, M-C.; “Alarms in the intensive care unit: how can the number of false alarms be reduced?”, Critical Care Aug. 2001, vol. 5 No. 4; p. 1-5.Applicant
- Eldor et al., “A device for monitoring ventilation during anaesthesia; the paratracheal audible respiratory monitor”, Canadian Journal of Anaesthesia, 1990, vol. 9, No. 1, p. 95-98.Applicant
- Gorges, M. et al; “Improving Alarm Performance in the Medical Intensive Care Unit Using Delays and Clinical Context”; Technology, Computing, and Simulation; vol. 108, No. 5, May 2009; p. 1546-1552.Applicant
- Imhoff, M. et al; “Alarm Algorithms in Critical Care Monitoring”; Anesth Analg 2006;102:1525-37.Applicant
- International Search Report & Written Opinion, PCT Application PCT/US2010/052758, Feb. 10, 2011; 12 pages.Applicant
- International Search Report & Written Opinion, PCT Application PCT/US2010/058981, Feb. 17, 2011; 11 pages.Applicant
- International Search Report and Written Opinion issued in application No. PCT/US2010/052756 on Feb. 6, 2012.Applicant
- International Search Report, PCT Application PCT/CA2003/000536, Dec. 11, 2003; 2 pages.Applicant
- International Search Report, PCT Application PCT/US2009/069287, Mar. 30, 2010; 7 pages.Applicant
- Japanese Office Action for JP Application No. 2007-506626 mailed Mar. 1, 2011.Applicant
- Sierra et al., Monitoring Respiratory Rate Based on Tracheal Sounds. First Experiences, Proceedings of the 26th Annual Int'l Conf. of the IEEE EMBS (Sep. 2004), 317-320.Applicant
- Supplementary Partial European Search Report for International Application No. 05732095.4, dated Jun. 26, 2009 in 4 pages.Applicant
- Watt, R. C.; “Alarms and Anesthesia. Challenges in the design of Intelligent systems for Patient Monitoring”; IEEE Engineering in Medicine and biology; Dec. 1993, p. 34-41.Applicant
- Welch Allyn, ECG ASIC, Product Data Sheet, 2001.Applicant
- Theimer et al., “Definitions of audio features for music content description”, Algorithm Engineering Report TR08-2-001, Feb. 2008.Applicant
- Stewart, C., Larson, V., “Detection and classification of acoustic signals from fixed-wing aircraft,” Systems Engineering, CH3051-0/91/0000-0025, IEEE, 1991.Applicant